WO2014100323A1 - Polycyclic-carbamoylpyridone compounds and their pharmaceutical use - Google Patents
Polycyclic-carbamoylpyridone compounds and their pharmaceutical use Download PDFInfo
- Publication number
- WO2014100323A1 WO2014100323A1 PCT/US2013/076367 US2013076367W WO2014100323A1 WO 2014100323 A1 WO2014100323 A1 WO 2014100323A1 US 2013076367 W US2013076367 W US 2013076367W WO 2014100323 A1 WO2014100323 A1 WO 2014100323A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- mmol
- hiv
- hydrogen
- reaction mixture
- Prior art date
Links
- 0 CC*=*CNC(C(C1=O)=CN(CC(N2IC3CC2)N3C2=*)C2=C1O)=O Chemical compound CC*=*CNC(C(C1=O)=CN(CC(N2IC3CC2)N3C2=*)C2=C1O)=O 0.000 description 34
- PVAVBBCVIDHSBK-UHFFFAOYSA-N C=Cc1c(CN)nccc1 Chemical compound C=Cc1c(CN)nccc1 PVAVBBCVIDHSBK-UHFFFAOYSA-N 0.000 description 1
- LYQXVXRCIAESDK-UHFFFAOYSA-N CC(C)C(CN(C)C)F Chemical compound CC(C)C(CN(C)C)F LYQXVXRCIAESDK-UHFFFAOYSA-N 0.000 description 1
- WOGITYHRGMMISV-UHFFFAOYSA-N CC(CC(F)=C1)C(CN)=C1F Chemical compound CC(CC(F)=C1)C(CN)=C1F WOGITYHRGMMISV-UHFFFAOYSA-N 0.000 description 1
- WUJKDBUOMLVZEO-UHFFFAOYSA-N CCC(CC)CC(C)C(C)N(C)N Chemical compound CCC(CC)CC(C)C(C)N(C)N WUJKDBUOMLVZEO-UHFFFAOYSA-N 0.000 description 1
- UTAMQUKCUIRBOR-UHFFFAOYSA-N CCc(ccc(F)c1)c1[I]=C Chemical compound CCc(ccc(F)c1)c1[I]=C UTAMQUKCUIRBOR-UHFFFAOYSA-N 0.000 description 1
- IFDWHPDLKUUBIL-JYBOWCNBSA-N COC1=C(C(N2[C@@](C3)(N)OC4C[C@H]2CC4)=O)N3C=C(C(O)=C)C1=O Chemical compound COC1=C(C(N2[C@@](C3)(N)OC4C[C@H]2CC4)=O)N3C=C(C(O)=C)C1=O IFDWHPDLKUUBIL-JYBOWCNBSA-N 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N NC1CCCCC1 Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- KQUJSUKOATYPTM-UHFFFAOYSA-N NCC(C(C1)F)=CC=C1F Chemical compound NCC(C(C1)F)=CC=C1F KQUJSUKOATYPTM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- HIV human immunodeficiency vims
- Human immunodeficiency virus infection and related diseases are a major public health problem worldwide.
- Human immunodeficiency vims type 1 (HTV-1) encodes three enzymes which are required for viral replication: reverse transcriptase, protease, and integrase.
- reverse transcriptase a enzyme which is required for viral replication
- protease a enzyme which is required for viral replication
- integrase integrase.
- drugs targeting reverse transcriptase and protease are in wide use and have shown effectiveness, particularly when employed in combination, toxicity and development of resistant strains have limited their usefulness (Palella, et al. N. Engl. J Med, (1998) 338:853 -860; Richman, D. D. Nature (2001) 410:995-1001).
- PXR Pregnane X receptor
- Activation of PXR is known to up-regulate or induce the production of metabolic enzymes such as cytochrome P450 3A4 (CYP3A4) as well as enzymes involved in transport, such as OATP2 in the liver and intestine (Endocrine Reviews (2002) 23(5): ⁇ 87-702).
- CYP3A4 cytochrome P450 3A4
- OATP2 oxygen species
- PXR activation it is desirable to minimize PXR activation. Further, it is known that PXR is activated by many different classes of molecules [Endocrine Reviews (2002) 23(5):687-702). Thus for drugs that will be co-administered with other drugs, it is important to test for and minimize PXR activation.
- Transporters have been identified as playing a role in the pharmacokinetic, safety and efficacy profile or drugs, and certain drug-drug interactions are mediated by transporters. See, Giacomini KM, et al. ""Membrane transporters in drug development,” NaLRev Drug Discov. 9: 215-236, 2010; Zhang L, et al. "Transporter- Mediated Drug-Drug Interactions,” Clin. Pharm. Ther. 89(4):481-484 (2011).
- OCT2 organic cation transporter 2
- SLC22A2 solute carrier
- MATE multidrug and toxin extrusion
- Inhibition of OCT2 can thus lead to increased levels of serum creatinine and the potential for increased levels of other OCT2 substrates, it is important as well to test and reduce OCT2 inhibition of drugs.
- a goal of antiretroviral therapy is to achieve viral suppression in the HIV infected patient.
- Treatment guidelines published by the United States Department of Health and Human Services provide that achievement of viral suppression requires the use of combination therapies, i.e., several drugs from at least two or more dr g classes.
- combination therapies i.e., several drugs from at least two or more dr g classes.
- the present invention is directed to novel polycyclic carbamoylpyridone compounds, having antiviral activity, including stereoisomers and pharmaceutical [y acceptable salts thereof, and the use of such compounds in the treatment of HIV infections.
- the compounds of the invention may be used to mhibit the activity of HIV integrase and may be used to reduce HIV replication.
- X is ⁇ () ⁇ or -NZ 3 - or -CHZ 3 -;
- W is -CHZ 2 -;
- Z 1 , Z z and Z 3 are each, independently, hydrogen or Cj -3 alkyl, or wherein Z 1 and Z 2 or Z 1 and Z 3 , taken together, form -L- wherein L is -C(R a ) 2 -, -C(R a ) 2 C(R a ) 2 -, -C(R a ) 2 C(R a ) 2 C(R a ) 2 -, or -C(R a ) 2 C(R a ) 2 C(R a ) 2 C(R a ) 2 -, wherein at least one of Z 1 and Z 2 or Z x and Z 3 , taken together, form -L-; Z is a bond, -CH 2 -, or ⁇ ( !! ( I !> ⁇ ;
- Y 1 and Y 2 are each, independently, hydrogen, Cj-aalkyl or R 3 ⁇ 4 is phenyl substituted with one to three halogens;
- each R 3 is, independently, hydrogen, halo, hydroxyl or ( ' ⁇ salky].
- X is -O- or -NZ 3 - or -CHZ 3 -;
- W is -O- or -NZ 2 - or -CHZ 2 -:
- Z 1 , Z 2 and Z 3 are each, independently, hydrogen or C 1-3 alkyl, or wherein Z 1 and Z 2 or Z l and Z 3 , taken together, form -L- wherein L is -C(R a ) 2 -, -C(R a ) 2 C(R a ) 2 -, -C(R a ) 2 C(R a ) 2 C(R a )2-, -C(R a ) 2 C(R a ) 2 C(R a ) 2 C(R a )2-, -C(R a ) 2 OC(R a ) 2 -,
- Z is a bond or -CH 2 -, ⁇ ( ' !! . ⁇ ( H . -. -CH 2 CH 2 CH 2 -, -CH 2 OCH 2 -, -CH 2 NR a CH 2 -, -CH 2 SCH 2 -,-CH 2 S(0)CH 2 - or -CH 2 S0 2 CH 2 -;
- Y 1 and Y i are each, independently, hydrogen, or Ci.3h.al0al.kyl, or Y 1 and Y 2 , together with the carbon atom to which they are attached, form a carbocyclic ring having from 3 to 6 ring atoms or a heterocyclic ring having from 3 to 6 ring atoms, wherein the carbocyciic or heterocyclic ring is optionally substituted with one or more R ;
- R 5 is optionally substituted aryl or optional!)' substituted heteroaryl; and each R a is, independently, hydrogen, halo, hydroxyl or C 1 . 4 alkyl, or wherein two R a groups, together with the carbon atom to which they are attached, form
- a pharmaceutical composition comprising a compound having Formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- the invention also provides the use of a pharmaceutical composition as described hereinabove for the treatment of an HIV infection in a human being having or at risk of having the infection.
- a method of using a compound having Formula (I) in therapy comprising administering to the mammal a compound having Formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- an article of manufacture comprising a composition effective to treat an HIV infection; and packaging material comprising a label which indicates that the composition can be used to treat infection by HIV is disclosed.
- exemplary compositions comprise a compound of Formula (I) according to this invention or a pharmaceutically acceptable salt thereof.
- a method of inhibiting the replication of HIV comprises exposing the virus to an effective amount of the compound of Formula (I), or a salt thereof, under conditions where replication of HIV is inhibited.
- a compound of Formula (I) or “compounds of Formula (I)” refers to ail embodiments of Formula (I), including, for example, compounds of Formulas (II-A), (II-B), (II-C), (III-A), ( ⁇ - ⁇ ), (III-C), (III-D), (II -E), (III-F), (ITI-G), (III-H), (IV-AA), (IV-AB), (IV-AC), (TV-AD), (IV-AE), (IV-AF), (TV-AG), (IV-AH), (IV-BA), (IV-BB), (IV-BC), (IV-BD), (IV-BE), (IV-BF), (IV-BG), and (IV-BH), as well as the specific compounds disclosed herein.
- Amino refers to the -N3 ⁇ 4 radical.
- Niro refers to the -N0 2 radical.
- Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which is saturated or unsaturated ⁇ i.e., contains one or more double and/or triple bonds), having from one to twelve carbon atoms (Ci-Cj?
- alkyl preferably one to eight carbon atoms (Cj-Cg alkyl) or one to six carbon atoms (Ci-Ce alkyl), and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, H-propyl, l-rnethylethyl (zso-propyl), «-butyl, n-pentyl, 1 ,1-dirnethylethyl (/-butyl), 3-methylhexyl, 2-meth.ylh.exyi, etherryl, prop-l-enyl, but-l -enyl, pent-l-enyl, penta-l.,4-dienyl, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
- an alkyl group may be optionally substituted
- Alkylene or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, which is saturated or unsaturated (i.e., contains one or more double and/or triple bonds), and having from one to twelve carbon atoms, e.g., methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, « ⁇ butynylene, and the like.
- the alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond.
- the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain may be optionally substituted.
- Alkoxy refers to a radical of the formula -ORA where R A is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted.
- Alkylamino refers to a radical of the formula -NHR A or -NR A RA where each is, independently, an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted.
- Thioalkyl refers to a radical of the formula -SRA where A is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group may be optionally substituted.
- Aryl refers to a monocylic hydrocarbon ring system radical comprising hydrogen and 6 to 18 carbon atoms.
- Aryl radicals include, but are not limited to, aryl radicals derived from benzene.
- aryl or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals that are optionally substituted.
- Araikyi refers to a radical of the formula -R B -RC where R B is an alkylene chain as defined above and c is one or more aryl radicals as defined above, for example, benzyl. Unless stated otherwise specifically in the specification, an aralkyl group may be optionally substituted.
- Cycloalkyl or “carbocyclic ring” refers to a stable non-aromatic monocyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
- Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Unless otherwise stated specifically in the specification, a cycloalkyl group may be optionally substituted,
- Cycloalkylalkyl refers to a radical of the formula - B D where R B is an alkylene chain as defined above and is a cycloalkyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group may be optionally substituted.
- Halo or halogen refers to brorao, chloro, fluoro or iodo.
- Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difiuoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1 ,2-difluoroethyl, 3-bromo-2-fiuoropropy[, 1 ,2-dibromoethyi, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.
- Heterocyclyl or “heterocyclic ring” refers to a stable 3- to 18-membered non-aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
- the heterocyclyl radical is a monocyclic ring system; and the heterocyclyl radical may be partially or fully saturated.
- heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyi, [l,3]dithianyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpliQllnyl, 2-oxopiperazinyl, 2-oxopiperidinyL 2-oxopyrroiidinyl, oxazolidmyl, piperidinyi, piperazinyi, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1 -oxo-thiomorph.olinyl, and IJ -dioxo-thiomorphoiinyl. Unless stated otherwise specifically in the specification, a heterocyclyl,
- ⁇ '-heterocyc!y refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, an N-heterocyelyl group may be optionally substituted.
- Heterocyclylalkyl refers to a radical of the formula -R B R E where .
- R is an alkvlene chain as defined above and R E is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the afkyf radical at the nitrogen atom. Unless stated otherwise specifically in the specification, a heterocyclylalkyl group may be optionally substituted.
- Heteroaryl refers to a 5- to 14-membered monocyclic ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Examples include, but are not limited to, azepinyl, furanyl, furanonyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazoiyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1- oxidopyridinyl, 1 -oxidopyrimidinyl, 1-oxidopyrazinyi, 1 -oxidopyridazinyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazolyl, thiadiazolyi, triazolyl, tetrazolyl, triazinyl, thiopheny
- N-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl. radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an A/-heteroaryl group may be optionally substituted.
- Heteroarylalkyl refers to a radical of the formula --R B R F where R B is an alkylene chain as defined above and Rp is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group may be optionally substituted.
- substituted means any of the above groups (i.e., alkyl, alkylene, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloaikylalkyl, haloalkvl, heterocyclyl, N-heterocyciyl, heterocyclylalkyl, heteroaryl, .V-heteroaryl and/or heteroaryialkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, CI, Br
- RG and R H are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryi, aralkyl, cycloaikyi, cycloalkylalkyl, haloalkyl, heterocyclyi, N-heterocyclyl, heterocyelylalkyl, heteroaryl, N-heteroaryl and/or heteroaryialkyl.
- Substituted further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, iraino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloaikyi, cycloalkylalkyl, haloalkyl, heterocyclyi, ⁇ -heterocyclyl, heterocvclyiaikyi, heteroaryl, ⁇ -heteroaryl and/or heteroaryialkyl group, in addition, each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
- protecting group refers to a labile chemical moiety which is known in the art to protect reactive groups including without limitation, hydroxyl and amino groups, against undesired reactions during synthetic procedures. Hydroxy! and amino groups protected wit a protecting group are referred to herein as “protected hydroxy! groups” and “protected amino groups”, respectively. Protecting groups are typically used selectively and/or orthogonally to protect sites during reactions at other reactive sites and can then be removed to leave the unprotected group as is or available for further reactions. Protecting groups as known in the art are described generally in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999).
- groups are protected or present as a precursor that will be inert to reactions that modify other areas of the parent molecule for conversion into their final groups at an appropriate time. Further representative protecting or precursor groups are discussed in Agrawal, et al., Protocols for Oligonucleotide Conjugates, Eds, Humana Press; New Jersey, 1994; Vol. 26 pp. 1-- 72. Examples of "hydroxy!
- protecting groups include, but are not limited to, t-butyl, t- butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, l-(2- chloroethoxy)ethyl, 2-trimethylsilylethyl, ⁇ -chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichiorobenzyi, diphenylmethyl, p-nitrobenzyl, triphenylmethyl, trimethyisiiyl, triethylsilyl, t-butyidimethylsiiyi, t-butyldiphenylsilyl (TBDPS), triphenyisiiyl, benzoylformate, acetate, chloroacetate, trichloroacetate, triiluoroacetate, pivaloate, benzoate, p-phenylbenzoate, 9-fiuorenylmethyl carbon
- amino protecting groups include, but are not limited to, carbamate - protecting groups, such as 2-trirnethylsilylethoxycarbonyi (Teoc), 1 -methyl- 1 -(4- biphenyiyl)ethoxyearhonyl (Bpoc), t-butoxycarbonyl (BOC), allyloxycarbonyl (Alloc), 9-fluorenylmethyloxycarbonyl (Fmoc), and benzyloxycarbonyl (Cbz); amide protecting groups, such as formyi, acetyl, trihaloacetyl, benzoyl, and nitrophenylacetyi; sulfonarai de-protecting groups, such as 2 ⁇ nitrobenzenesulfonyl; and imine and cyclic imide protecting groups, such as phthalimido and dithiasuccinoyl.
- carbamate - protecting groups such as 2-trirnethylsilylethoxycarbonyi (T
- the invention disclosed herein is also meant to encompass all pharmaceutically acceptable compounds of Formula (I) being isotopicaliy-labeled by having one or more atoms re laced by an atom having a different atomic mass or mass number.
- isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, H C, i3 C, i4 C, 13 N, 15 N, !5 0, 17 0, 18 0, 31 P, 32 P, 5 S, l8 F, Jb Cl, i 3 l, and respectively.
- radiolabeled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action, or binding affinity to pharmacologically important site of action.
- Certain isotopically-labeled compounds of Formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
- the radioactive isotopes tritium, i.e. " ⁇ , and carbon- 14, i.e. i4 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- Substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability. For example, in vivo half-life may increase or dosage requirements may be reduced. Thus, heavier isotopes may be preferred in some circumstances.
- isotopically-labeled compounds of Formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- the invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterifi cation, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising administering a compound of this invention to a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically identified by administering a radiolabeled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
- an animal such as rat, mouse, guinea pig, monkey, or to human
- “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
- “Mammal” includes humans and both domestic animals such as laboratory animals and household pets ⁇ e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
- Optional or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
- optionally substituted aryl means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
- “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
- “Pharmaceutically acceptable salt” refers to a salt of a compound that is pharmaceutically acceptable and that possesses (or can be converted to a form that possesses) the desired pharmacological activity of the parent compound.
- “pharmaceutically acceptable salts” of the compounds disclosed herein include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth metal (for example, magnesium), ammonium and X 4 " (wherein X is C J -C4 alkyl).
- Pharmaceutically acceptable salts of a nitrogen atom or an amino group include for example salts of organic carboxylic acids such as acetic, benzoic, camphorsulfonic, citric, glucoheptonic, gluconic, lactic, fumaric, tartaric, maleic, malonic, malic, mandelic, isethionic, lactobionic, succinic, 2-napththalenesulfomc, oleic, palmitic, propionic, stearic, and trimethyl acetic acids; organic sulfonic acids, such as methanesulfonic, ethanesulfonic, benzenesuifonic and p-toluenesulfonic acids; and inorganic acids, such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and sulfamic acids.
- organic carboxylic acids such as acetic, benzoic, camphorsulfonic, citric, glucohe
- Pharmaceutically acceptable salts of a compound of a hydroxy group include the anion of said compound in combination with a suitable cation such as Na ; and NX 4 f (wherein is independently selected from H or a C 1 --C 4 alkyl group).
- Pharmaceutically acceptable salts also include salts formed when an acidic proton present, in the parent compound is replaced by either a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aiurmnum ion; or coordinates with an organic base such as diemano famine, triethanolamine, N-methylg!ucamine and the like. Also included in this definition are ammonium and substituted or quaternized ammonium salts.
- salts of active ingredients of the compounds disclosed herein will typically be pharmaceutically acceptable, i.e. they will be salts derived from a physiologically acceptable acid or base.
- salts of acids or bases which are not pharmaceutically acceptable may also find use, for example, in the preparation or purification of a compound of Formula (I) or another compound of the invention. All salts, whether or not derived from a physiologically acceptable acid or base, are within the scope of the present invention.
- Metal salts typically are prepared by reacting the metal hydroxide with a compound of this invention.
- metal salts which are prepared in this way are salts containing Li + , Na + , and K + .
- a less soluble metal salt can be precipitated from the solution of a more soluble salt by addition of the suitable metal compound.
- compositions herein comprise compounds disclosed herein in their un-ionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.
- solvate refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent.
- the solvent may be water, in which case the solvate may be a hydrate.
- the solvent may be an organic solvent.
- the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding soivated forms.
- the compound of the invention may be true solvates, while in other cases, the compound of the invention may merely retain adventitious water or be a mixture of water plus some adventitious solvent.
- a “pharmaceutical composition” refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans.
- a medium includes ail pharmaceutically acceptable carriers, diluents or excipients therefor.
- Effective amount refers to an amount of a compound according to the invention, which when administered to a patient in need thereof, is sufficient to effect treatment for disease-states, conditions, or disorders for which the compounds have utilit . Such an amount would be sufficient to elicit the biological or medical response of a tissue system, or patient that is sought by a researcher or clinician.
- the amount of a compound according to the invention which constitutes a therapeutically effective amount will vary depending on such factors as the compound and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of the treatment, the type of disease-state or disorder being treated and its severity, dmgs used in combination with or coincidentally with the compounds of the invention, and the age, body weight, general health, sex and diet of the patient.
- a therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the state of the art, and this disclosure.
- treatment is intended to mean the administration of a compound or composition according to the present invention to alleviate or eliminate symptoms of HIV infection and/or to reduce viral load in a patient.
- treatment also encompasses the administration of a compound or composition according to the present invention post-exposure of the individual to the vims but before the appearance of symptoms of the disease, and/or prior to the detection of the virus in the blood, to prevent the appearance of symptoms of the disease and/or to prevent the virus from reaching detectibie levels in the blood, and the administration of a compound or composition according to the present invention to prevent perinatal transmission of HIV from mother to baby, by administration to the mother before giving birth and to the child within the first days of life.
- antiviral agent as used herein is intended to mean an agent (compound or biological) that is effective to inhibit the formation and/or replication of a virus in a human being, including but not limited to agents that interfere with either host or viral mechanisms necessary for the formation and/or replication of a virus in a human being.
- inhibitor of HIV replication is intended to mean an agent capable of reducing or eliminating the ability of HIV to replicate in a host cell, whether in vitro, ex vivo or in vivo.
- the compounds of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (5)- or, as (D)- or (L)- for amino acids.
- the present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms.
- Optically active (+) and (-), (2?)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
- stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
- the present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
- a “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
- the present invention includes tautomers of any said compounds.
- a “prodrug” refers to a compound that is chemically designed to efficiently liberate the parent dmg after overcoming biological barriers to oral delivery.
- the present invention includes prodrugs of the compounds of Formula (I).
- X is -O- or -NZ 3 - or -CHZ 3 -;
- W is -CHZ 2 -;
- Z J , Z 2 and Z 3 are each, independently, hydrogen or C 1-3 alkyl, or wherein Z 1 and Z 2 or Z 1 and Z 3 , taken together, form -L- wherein L is -C(R a ) 2 ⁇ , -C(R a ) 2 C(R a ) 2 -, -C(R a ) 2 C(R a ) 2 C(RV, or -C(R a ) 2 C(R a ) 2 C(R a ) 2 C(R a ) 2 -, wherein at least one of Z 1 and Z 2 or Z 5 and Z ' , taken together, form -L-;
- Z 4 is a bond, -CH 2 -, or -CH 2 CH 2 -;
- Y' and Y "6 are each, independently, hydrogen.
- R 1 is phenyl substituted with one to three halogens;
- each R a is, independently, hydrogen, halo, hydroxy! or C. ⁇ alkyL
- compounds having the following f ormula (I l-B):
- I. is -C(R a ) 2 -.
- I, is ⁇ C(R a ) 2 C(R a ) 2 C(R a ) 2 -.
- each R a is hydrogen.
- one R is methyl and each remaining R. a is hydrogen.
- one R a is halogen and each remaining R a is hydrogen.
- two R a are halogen and each remaining R a is hydrogen.
- one R a is halogen and each remaining R a is hydrogen.
- X is -0-. In another embodiment, X is -NZ 3 -. In another embodiment, X is -NH-. 16, In another embodiment, X is -CHZ 3 - and Z 1 and Z J , taken together, form -L-. In a further embodiment, 7 is hydrogen. In another embodiment, X is -CH 2 -.
- Z is a bond or -CH 2 -. In another embodiment,
- Z 4 is -CH 2 -. In another embodiment, Z 4 is a bond.
- Y 1 and Y 2 are each independently hydrogen, methyl or trifluoromethyl.
- R 1 is substituted with one halogen.
- R 1 is 4-fluorophenyi or 2-fluoropheiiyL
- R 1 is substituted with two halogens.
- R 1 is 2,4-d.ifiuorophenyl, 2,3-difIuorophenyl, 2,6-difIuorophenyl, 3- fluoro-4-chlorophenyl, 3,4-difluorophenyl, 2-fj.uoro-4-chloroph.enyl, or 3,5- difluorophenyl.
- R 1 is 2,4-difiuorophenyl.
- R ! is substituted with three halogens.
- R 1 is 2,4,6-trifluorophenyl or 2,3,4-trifluorophenyl. In still a further embodiment, R 1 is 2,4,6-trifluorophenyl.
- a pharmaceutical composition comprising a compound of any one of the Formulas (I), ( ⁇ - ⁇ ), ( ⁇ - ⁇ ), or (II-C), as noted above, or a stereoisomer or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient.
- Another embodiment is provided comprising a method of treating an HIV infection in a human having or at risk of having the infection by administering to the human a therapeutically effective amount of a compound of any one of the Formulas (I), (II-A), (II-B), or (II-C), as noted above, or a pharmaceutical composition thereof.
- Another embodiment is provided comprising a method of treating or preventing an HIV infection in a human having or at risk of having the infection by administering to the human a therapeutically effective amount of a compound of any one of the Formulas (I), (II-A), (II-B), or (II-C), as noted above, or a pharmaceutical composition thereof.
- the use of a compound of any one of the Formulas (I), (II-A), (II-B), or (II-C), as noted above, or a pharmaceutical composition thereof, for the treatment of an HIV infection in a human having or at risk of having the infection is provided.
- the use of a compound of any one of the Formulas (I), (I l-A), (II-B), or (II-C), as noted above, or a pharmaceutical composition thereof, for the treatment or prevention of an HIV infection in a human having or at risk of having the infection is provided.
- the use of a compound of any one of the Formulas (I), (II-A), (II-B), or (II-C), as noted above, or a pharmaceutical composition thereof, for use in the therapeutic treatment of an HIV infection is provided.
- the use of a compound of any one of the Formulas (I), (II-A), (II-B), or (II-C), as noted above, or a pharmaceutical composition thereof, for use in the prophylactic or therapeutic treatment of an HIV infection is provided.
- X is -O- or -NZ 3 - or -CHZ 3 -;
- W is -()- or -NZ 2 - or -CHZ 2 -;
- Z 1 , Z 2 and ⁇ ⁇ are each, independently, hydrogen, Ci-salkyl or C 1 -3 haloalkyl, or wherein Z 1 and Z z or Z 1 and Z J , taken together, form -L- wherein L is
- Z 4 is a bond or -( ⁇ , - . - C I I C f I - , -CH 2 CH 2 CH 2 -, -CH 2 OCH 2 -, -CH 2 NR a CH 2 -, -CH 2 SCH 2 -,-CH 2 S(0)CH 2 - or -CH 2 SG 2 CH 2 -;
- Y 1 and Y 2 are each, independently, hydrogen or or Y 1 and Y , together with the carbon atom to which they are attached, form a carbocyclic ring having from 3 to 6 ring atoms or a heterocyclic ring having from 3 to 6 ring atoms, wherein the carbocyclic or heterocyclic ring is optionally substituted with one or more R a ;
- R 3 ⁇ 4 is optionally substituted aryl or optionally substituted heteroaryl; and each R a is, independently, hydrogen, halo, hydroxy! or or wherein two R a groups, together with the carbon atom to which they are attached, form
- W is -CHZ ' -.
- Z 1 and Z" or Z 1 and Z 3 taken together, form -L-.
- compounds are provided having one of the following Formulas ( ⁇ - ⁇ ), (II-B), or (I!-C):
- L is -C(R a ) 2 C(R a ) 2 -, -C(R a ) 2 C(R a ) 2 C(R a ⁇ 2-
- Y 1 and Y% together with the carbon atom to which they are attached form a carbocyclic ring having from 3 to 6 ring atoms or a heterocyclic ring having from 3 to 6 ring atoms.
- compounds having one of the following Fomiulas (III-A), (III-B), (III-C) or (III-D):
- Z 1 and Z 3 are each, independently, hydrogen or
- compounds are provided having one of the following Formulas (III-E), ( ⁇ -F), ( ⁇ -G) or (III ⁇ H):
- compounds are provided having one of the followmg Fomiulas (IV-AA), (TV-AB), (IV-AC), (IV-AD), (IV-AE), (IV-AF), (IV-AG) or (IV- AH):
- L is -C(R a )2-, -C(R a ) 2 C(R a ) 2 -, -C(R a ) 2 CiR a ) 2 C(R a ) 2
- compounds are provided having one of the following Formulas (IV-BA), (IV-BB), (IV-BC), (IV-BD), (IV-BE), (IV-BF), (IV-BG) or (IV-BH):
- I . is -C(R a ) 2 ⁇ , -C(R a ) 2 C(R a ) 2 -,
- each R a is hydrogen.
- one R a is methyl and each remaining R a is hydrogen.
- one R a is halogen and each remaining R a is hydrogen. In still a further embodiment, two R a are halogen and each remaining R a is hydrogen. In still a further embodiment, one R a is halogen and each remaining R a is hydrogen.
- L is -C(R a ) 2 OC(R a ) 2 -, -C(R a ) 2 NR a C(R a ) 2 ⁇ , -C(R a ) 2 SC(R a ) 2 - > -C(R a ) 2 S(0)C(R a ) 2 -, or -C(R a ) 2 S0 2 C(R a ) 2 -.
- L is -C(R a ) 2 OC(R a ) 2 -.
- each R is hydrogen.
- one R is methyl and each remaining R a is hydrogen, in still a further embodiment, one R a is halogen and each remaining R a is hydrogen. In still a further embodiment, two R a are halogen and each remaining R a is hydrogen. In still a further embodiment, one R d is halogen and each remaining R is hydrogen .
- X is -0-. In a further embodiment, Z" is hydrogen. In another embodiment, X is - ⁇ , In another embodiment, is -NH-. In another embodiment, X is -CHZ 3 -. In another embodiment, X is -CH? ⁇ .
- Z 4 is a bond or ⁇ CH 2 ⁇ . In another embodiment, Z 4 is -CH ? -. In another embodiment, Z 4 is a bond.
- Y 1 and are each independently hydrogen, methyl or trifluoromethyi.
- R 1 is substituted with one halogen.
- R 1 is 4-fiuorophenyl or 2-fluorophenyl.
- R 1 is phenyl. In another embodiment, R 1 is pyridinyl.
- R ! is substituted with at least one halogen.
- R 1 is substituted with one halogen.
- R 1 is 4-fluorophenyi or 2-fluorophenyl.
- R 1 is substituted with two halogens.
- R 1 is 2,4-difluorophenyl, 2,3-difluorophenyl, 2,6-d.ifluorophenyl, 3- fl.uoro-4-chlorophenyl, 3,4-difluorophenyl, 2-fl.uoro-4-chloroph.enyl, or 3,5- difluorophenyl.
- R 1 is 2,4-difluorophenyl.
- R ! is substituted with three halogens.
- R 1 is 2,4,6-trifluorophenyl or 2,3,4-trifluorophenyl. In still a further embodiment, R 1 is 2,4,6-trifluorophenyl.
- R 1 is 3-trifluoromethyl-4-fluorophenyl or 2- cyclopropoxy-4-fluorophenyl.
- a pharmaceutical composition comprising a compound of any one of Formulas (I), (II-A.), (II-B), (I !-C), ( ⁇ - ⁇ ), (HI-B), (II l-C), (III-D), (II l-E), (III-F), (III-G), (III-H), (IV-AA), ( I V- ⁇ ). ( IV- ⁇ .
- Another embodiment comprising a method of treating an HIV infection in a human having or at risk of having the infection by administering to the human a therapeutically effective amount of a compound of any one of Formulas (I), (II-A), (II-B), (II-C), (IIl-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-G), (IIl-H), (IV-AA), (IV-AB), (IV-AC), (IV-AD), (IV-AE), (IV-AF), (IV-AG), (IV-AH), (IV-BA), (IV-BB), (IV-BC), (IV-BD), (IV-BE), (IV-BF), (IV-BG), and (IV-BH), as noted above, or a pharmaceutical composition thereof.
- Another embodiment comprising a method of treating or preventing an HIV infection in a human having or at risk of having the infection by administering to the human a therapeutically effective amount of a compound of any one of Formulas (I), (I I -A), (II-B), (II-C), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-G), (III-H), (IV-AA), (IV-AB), (IV-AC), (IV-AD), (IV-AE), (IV-AF), (IV-AG), (IV-AH), (IV-BA), (IV-BB), (IV-BC), (IV-BD), (IV-BE), ( IV-BF), (IV-BG), and (IV-BH), as noted above, or a pharmaceutical composition thereof.
- IV-AA (IV-AA), (IV- AB), (TV-AC), (IV-AD), (IV-AE), (IV-AF), (IV-AG), ( I V-Al l h (IV-BA), (IV-BB), (IV-BC), (IV-BD), (IV-BE), (IV-BF), (IV-BG), and (IV-BH), as noted above, or a pharmaceutical composition thereof, for use in the prophylactic or therapeutic treatment of an HIV infection is provided.
- the Compound 3 of Example 3 may be shown as:
- the compounds described herein are administered as a raw chemical or are formulated as pharmaceutical compositions.
- Pharmaceutical compositions disclosed herein include a compound of Formula (]) and one or more of: a pharmaceutically acceptable carrier, diluent or excipient.
- the compound of Formula (I) is present in the composition in an amount which is effective to treat a particular disease or condition of interest.
- the activity of compounds of Formula (I) can be determined by one skilled in the art, for example, as described in the Examples below. Appropriate concentrations and dosages can be readily determined by one skilled in the art.
- a compound of Formula (I) is present in the pharmaceutical composition in an amount from about 25 mg to about 500 mg.
- a compound of Formula (I) is present in the pharmaceutical composition in an amount of about 100 mg to about 300 mg. In certain embodiments, a compound of Formula (I) is present in the pharmaceutical composition in an amount of about 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg or about 500 mg.
- compositions of the invention are prepared by combining a compound of the invention with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and in specific embodiments are formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols.
- compositions of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient.
- Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the invention in aerosol form may hold a plurality of dosage units.
- composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings described herein.
- compositions disclosed herein are prepared by methodologies well known in the pharmaceutical art.
- a pharmaceutical composition intended to be administered by injection is prepared by combining a compound of the invention with sterile, distil led water so as to form a solution
- a surfactant is added to facilitate the formation of a homogeneous solution or suspension.
- Surfactants are compounds that non-covalentiy interact with the compound of the invention so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.
- the compounds of the invention are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed ; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy.
- a method for treating or preventing an HIV infection in a human having or at risk of having the infection comprising administering to the human a therapeutical!)' effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents.
- compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent or excipient are provided.
- combination pharmaceutical agents comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more additional therapeutic agents are provided.
- the additional therapeutic agent may be an anti-HIV agent.
- the additional therapeutic agent is selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV mtegrase inhibitors, HIV non- catalytic site (or allosteric) integrase inhibitors, entry inhibitors (e.g., CCR5 inhibitors, gp41 inhibitors (i.e., fusion inhibitors) and CD4 attachment inhibitors), CXCR4 inhibitors, gpl20 inhibitors, G6PD and NADH-oxidase inhibitors, compounds that target the HIV capsid ("capsid inhibitors"; e.g., capsid polymerization inhibitors or capsid disrupting compounds such as those disclosed in WO 2013/006738 (Gilead Sciences), US 2013/0
- HIV protease inhibitors selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-1 14, mozenavir (DMP- 450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-10G, DG35, and AG 1859;
- HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase selected from the group consisting of capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC-961 , DPC- 963, MIV-150, TMC-120, rilpivirene, BILR 355 BS, VRX 840773, lersivirine (UK- 453061), RDEA806, KM023 and MK-1439;
- HIV nucleoside inhibitors of reverse transcriptase selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zaicitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, ⁇ -FTC, D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, apricitibine (AVX754), KP-1461, GS- 9131 (Giiead Sciences) and fosalvudine tidoxil (formerly HDP 99.0003);
- HI V nucleotide inhibitors of reverse transcriptase selected from the group consisting of tenofovir, tenofovir disoproxil fumarate, tenofovir alafenarnide fumarate (Giiead Sciences), GS-7340 (Giiead Sciences), GS-9148 (Giiead Sciences), adefovir, adefovir dipivoxii, CMX-001 (Chimerix) or CMX-157 (Chimerix);
- HIV integrase inhibitors selected from the group consisting of curcumm, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5- dicaffeoylquitiic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, AR-177, L-870812, and L-870810, raltegravir, BMS-538158, GS 364735C, BMS-707035, MK-2048, BA 01 1 , elvitegravir, dolutegravir and GSK- 744;
- NICKI aliosteric, integrase inhibitors
- NCINI aliosteric, integrase inhibitors
- BI-224436 CX0516, CX05045, CX14442
- compounds disclosed in WO 2009/062285 Boehrmger Ingelheim
- WO 2010/130034 Boehringer Ingelheim
- WO 2013/159064 Gilead Sciences
- WO 2012/145728 Gilead Sciences
- WO 2012/003497 Gilead Sciences
- WO 2012/003498 WO 2012/003498
- gp41 inhibitors selected from the group consisting of enfuvirtide, sifuvirfide, albuvirtide, FB006M, and TRI- 1144;
- CCR5 inhibitors selected from the group consisting of aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO- 140, 1 CB15050, PF-232798 (Pfizer), and CCR5mAb004;
- CD4 attachment inhibitors selected from the group consisting of ibaiizumab (TMB-355) and BMS-068 (BMS-663068);
- pharmacokinetic enhancers selected from the group consisting of cobicistat and SPI-452;
- PA-457 (bevirimat), HRG214, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDXOIO (ipilimumab), PBS 1 19, ALG 889, and PA-
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with two, three, four or more additional therapeutic agents. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents.
- the two, three four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, or they can be selected from different classes of therapeutic agents.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleotide inhibitor of reverse transcriptase and an HIV non-nucleoside inhibitor of reverse transcriptase.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleotide inhibitor of reverse transcriptase, and an HIV protease inhibiting compound.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and an HIV protease inhibiting compound.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleotide inhibitor of reverse transcriptase, an HI non-nucleoside inhibitor of reverse transcriptase, and a pharmacokinetic enhancer.
- the components of the composition are administered as a simultaneous or sequential regimen.
- the combination may be administered in two or more administrations.
- a compound disclosed herein is combined with one or more additional therapeutic agents in a unitar dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.
- a compound disclosed herein is administered with one or more additional therapeutic agents.
- Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more additional therapeutic agents, such that therapeutically effective amounts of the compound disclosed herein and one or more additional therapeutic agents are both present in the body of the patient.
- Co-administration includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents.
- a unit dose of a compound disclosed herein is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents.
- a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound disclosed herein within seconds or minutes.
- a unit dose of a compound disclosed herein is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents.
- a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound disclosed herein.
- Schemes 1-3 are provided as further embodiments of the invention and illustrate general methods which were used to prepare compounds having Formula (I) and which can be used to prepare additional compound having Fonnula (I),
- Al can be converted to amide A2 with an appropriate amine and a coupling reagent such as HATU or EDCI.
- A2 can be converted to A3 with a strong acid such as methanesulfonic acid.
- A3 can be converted to either A5 or A4 by heating with an appropriate cyclic diamine or cyclic aminoalcohol followed by methyl deprotection with a reagent such as magnesium bromide.
- Al can be converted to A6 by treatment with a strong acid suc as methanesulfonic acid.
- A6 can be condensed with an appropriate cyclic diamine or cyclic aminoalcohol followed by methyl deprotection with a reagent such as magnesium bromide to form either A7 or A8 respectively.
- A7 or A8 can be converted into amides A5 and A4 by treatment with an appropriate amine and a coupling reagent such as HATU or EDCI followed by methyl deprotection with a reagent such as magn esi urn bromide .
- Bl (as described in WO2012/018065) is condensed with diamine under reflux condition to give B2.
- B2 is hydrolyzed and coupled with an amine by an amide- forming method to afford product B3 upon removal of a benzyl protecting group.
- WO20.i l 1 19566 is incorporated herein by reference in its entirety.
- a suspension of Intermediate 5-A (24.8 mg, 0.080 mmol ), l-(2,4- difluoropheny].)cyclopropanamine HC1 salt (5-15, 21.9 mg, 0.107 mmol), and HATU (48 mg, 0.126 mmol) in CH 2 C1 2 (2 mL) was stirred at ambient temperature as N,N- diisopropylethyl amine (DIPEA) (0.1 mL, 0.574 mmol) was added.
- DIPEA N,N- diisopropylethyl amine
- reaction mixture was diluted with ethyl acetate before washing with 10% aqueous citric acid solution (xl) and saturated aqueous NaHC0 3 solution (xl). After the aqueous fractions were extracted with ethyl acetate (x l), the organic fractions were combined, dried (MgS0 4 ), and concentrated.
- Methyl 5-(2,4-difluorobenzy lcarbamoyl)- 1 -(2,2-dihydroxyethy i)-3- metboxy-4-oxo-l,4-dibydropyridine-2-carboxylate (l-C, 0,050 g, 0.121 mmol), (lS,3R)-3-aminocyclohexanol (0,028 g, 0.243 mmol) and potassium carbonate (0.034 g, 0.243 mmol) were suspended in acetonitrile (0.95 mL) and heated to 90 °C for 0.5 hour.
- reaction mixture was cooled and partitioned between dichloromethane and HQ (0.2 M aq). The layers were separated and the aqueous layer was extracted again with dichloromethane. The combined organic layers were treated with a small amount of acetonitrile, dried over sodium sulfate, filtered and concentrated.
- Methyl 5-(2,4-difluorobenzylcarbamoyl)- 1 -(2,2-dihydroxyethyl)-3- metiioxy-4-oxo-l ,4-diiiydropyridine-2-carboxyiate (l-C, 97.5 mg, 0.236 mmol) was treated with acetoiiitrile (1.9 mL), acetic acid (0, 1 mL), potassium carbonate (145 mg, 1 .05 fflfflol), and (8) ⁇ piperidm-3-amme dihydrochloride (82 rag, 0.472 rnmol). The reaction mixture was sealed and heated to 90 °C.
- the aqueous phase was thrice extracted into dichloromethane and the combined organic phases were combmed, dried over MgS0 4 , filtered, concentrated.
- the crude product was dissolved into acetonitrile (2 mL) and magnesium bromide (96.5 mg, 0.52 mmol) was added. The mixture was reseated and heated to 50 °C. After 80 minutes, the reaction mixture was quenched with ⁇ 5 mL of 0.2M HC1 (aq), the pH adjusted to - 10, diluted with brine, and thrice extracted into DCM. HPLC purification (Acetonitrile : water, 0.1% TFA) afforded Compound 20. !
- the reaction mixture was sealed and heated to 90 °C. After 60 minutes, the reaction mixture was cooled partitioned between brine and dichloromethane. The aqueous phase was thrice extracted into dichloromethane and the combined organic phases were combined, dried over MgS0 4 , filtered, and concentrated. The crude product was dissolved into acetonitrile (2 mL) and magnesium bromide (74 mg, 0.4 mrnol) was added. The mixture was resealed and heated to 50 °C. After 100 minutes, the reaction mixture was quenched with 0.2 ⁇ 1 HQ (aq), diluted with brine, and thrice extracted into DCM.
- the aqueous phase was thrice extracted into dichioromethane and the combined organic phases were combined, dried over MgS0 4 , filtered, and concentrated.
- the crude product was dissolved into acetoniirile (2 mL) and magnesium bromide (91 mg, 0.49 mmol ) was added. The mixture was resealed and heated to 50 °C. After 100 minutes, the reaction mixture was quenched with 0.2M HCl(aq), diluted with brine, and thrice extracted into DCM. HPLC purification (acetoniirile: water, 0.1% TFA) afforded Compound 22.
- Compound 29-B (13 mg, 14%) was prepared from compound 27-B (87 mg, 0,187 mmol) and the aminoalcohol 29-A (45 mg, 0.391 mmol) in a manner similar to that described in step 1 of the synthesis of compound 28-B.
- Compound 31-B (123 mg, 81%) was prepared from compound 27-B (150 mg, 0.322 mmol) and the aminoalcohol 31-A (70,3 mg, 0.695 mmol) in a manner similar to that described in step 1 and 2 of the synthesis of compound 30 ⁇ B.
- Cuprous cyanide (290 mg, 3,27 mmol) was suspended in 3.3 mL THF and cooled to -78 °C.
- a 1.6M solution of Me Li (4.1 mL, 6.56 mmol) in diethyl ether was added dropwise, the reaction solution was allowed to warm to room temperature over the course of 2 hours, and recooled to -78 °C.
- Intermediate 39-A (190 mg) was separated by chiral Prep-HP LC on a Lux Cellulose-2 column using 9: 1 ACN:MeOH as eluent to afford Intermediates 39-B (first eluting peak) and 40-A (second during peak) in enantioenriched form.
- Intermediate 39-B (absolute stereochemistry confinned by XRay crystallography), Chiral HPLC retention time ::: 3.98 minutes (Lux Cellulose-2 IC, 150 x 4.6 mm, 2 mL/min 9: 1 ACN:MeOH).
- Step 5 a
- the reaction mixture was allowed to warm to room temperature, 2,4-difluorobenzonitrile (3.48 g, 25 mmol) was added portionwise, and reaction temperature raised to 95 °C.
- the reaction solution was cooled to room temperature after stirring for 18 hours, diluted with ethyl acetate, washed twice with water and twice with brine, dried over MgS0 4 , filtered, and concentrated onto silica gel.
- Example 61 was prepared analogously to Example 60, substituting (1 S,3S,4R) ⁇ tert-b tyl 3-(aminomethy].)-2-azabicyclo[2.2. l]heptane-2-carboxylate (prepared in Example 55) for 41-E, and (3-ch].oro-2,4-dif3.uorophenyl)methanamine for (2,3- dichlorophenyl)methanamine.
- 'H-NMR 400 MHz, DMSO-d6) ⁇ 1 1.85 (s, 1 H), 10.45 (t, IH), 8.40 (s, I H), 7.37 (td, I I I ).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (60)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380073134.XA CN104995198B (en) | 2012-12-21 | 2013-12-19 | Polycyclic carbamoylpyridone compound and its medicinal usage |
AU2013361401A AU2013361401C1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR1020217012463A KR102351912B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
MDA20200093A MD4841B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
MX2015008009A MX344879B (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use. |
KR1020157019194A KR101770048B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
EP13815937.1A EP2822954B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
PL15201519T PL3067358T3 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CR20170279A CR20170279A (en) | 2012-12-21 | 2013-12-19 | POLYCHYCLIC CARBAMOILPIRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE |
CN202010188107.9A CN111303152B (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
DK13815937.1T DK2822954T3 (en) | 2012-12-21 | 2013-12-19 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE |
BR122015029881-4A BR122015029881B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic carbamoylpyridone compounds, pharmaceutical composition comprising them and their pharmaceutical use |
EA201591027A EA030003B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic carbamoylpyridone compound and pharmaceutical use thereof for treating hiv infection |
KR1020227001078A KR102406288B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
UAA201506209A UA114351C2 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
JP2015549669A JP6028105B2 (en) | 2012-12-21 | 2013-12-19 | Polycyclic carbamoylpyridone compound and pharmaceutical use thereof |
MDA20150064A MD4736C1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic carbamoylpyridone compound and its pharmaceutical use |
KR1020207015960A KR102246963B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
NZ709260A NZ709260A (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
BR112015014714-3A BR112015014714B1 (en) | 2012-12-21 | 2013-12-19 | polycyclic carbamoylpyridone compounds, pharmaceutical compositions comprising them and their pharmaceutical use |
SI201330197A SI2822954T1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
EP15201519.4A EP3067358B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR1020237014240A KR20230061576A (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR1020197031864A KR102120875B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CA2893843A CA2893843C (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
EP19185121.1A EP3608325B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
SG11201504857SA SG11201504857SA (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR1020177016697A KR102040007B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
EP22178867.2A EP4122935A1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR1020227018650A KR102527797B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
MX2017000362A MX357940B (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use. |
ES13815937.1T ES2577283T3 (en) | 2012-12-21 | 2013-12-19 | Polycyclic carbamoyl-pyridone compounds and their pharmaceutical use |
CN202310322212.0A CN116640140A (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoyl pyridone compounds and pharmaceutical uses thereof |
RS20160407A RS54873B1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
MDA20170067A MD4754C1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
MEP-2016-93A ME02400B (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
PH12019501848A PH12019501848A1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
IL239316A IL239316A (en) | 2012-12-21 | 2015-06-10 | Polycylic-carbamoylpyridone compounds and their pharmaceutical use |
HK15105909.2A HK1205124A1 (en) | 2012-12-21 | 2015-06-22 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
PH12015501445A PH12015501445A1 (en) | 2012-12-21 | 2015-06-22 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CR20150380A CR20150380A (en) | 2012-12-21 | 2015-07-17 | POLYCHYCLIC CARBAMOILPIRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE |
ZA2015/07997A ZA201507997B (en) | 2012-12-21 | 2015-10-26 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
PH12016500389A PH12016500389B1 (en) | 2012-12-21 | 2016-02-29 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
HK16104629.3A HK1216643A1 (en) | 2012-12-21 | 2016-04-21 | Polycyclic carbamoylpyridone compounds and their pharmaceutical use |
HRP20160544TT HRP20160544T1 (en) | 2012-12-21 | 2016-05-20 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
IL245780A IL245780B (en) | 2012-12-21 | 2016-05-23 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
SM201600157T SMT201600157B (en) | 2012-12-21 | 2016-06-01 | POLYCYCLIC CARBAMMYL PYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE |
IL247311A IL247311A0 (en) | 2012-12-21 | 2016-08-17 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
AU2016262722A AU2016262722B2 (en) | 2012-12-21 | 2016-11-24 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
LU00083C LUC00083I2 (en) | 2012-12-21 | 2018-08-17 | Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium |
LTPA2018511C LTC2822954I2 (en) | 2012-12-21 | 2018-08-21 | Polycyclic carbamoylpyridine compounds and their pharmaceutical applications |
NL300947C NL300947I2 (en) | 2012-12-21 | 2018-08-22 | Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium |
HUS1800035C HUS1800035I1 (en) | 2012-12-21 | 2018-08-23 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CY2018022C CY2018022I1 (en) | 2012-12-21 | 2018-08-23 | POLYCYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE |
AU2018232957A AU2018232957B2 (en) | 2012-12-21 | 2018-09-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CY20191101151T CY1122246T1 (en) | 2012-12-21 | 2019-11-05 | POLYCYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE |
AU2020202914A AU2020202914B2 (en) | 2012-12-21 | 2020-05-01 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
IL274988A IL274988A (en) | 2012-12-21 | 2020-05-28 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
AU2021221427A AU2021221427B2 (en) | 2012-12-21 | 2021-08-23 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
AU2023286038A AU2023286038A1 (en) | 2012-12-21 | 2023-12-30 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261745375P | 2012-12-21 | 2012-12-21 | |
US61/745,375 | 2012-12-21 | ||
US201361788397P | 2013-03-15 | 2013-03-15 | |
US61/788,397 | 2013-03-15 | ||
US201361845803P | 2013-07-12 | 2013-07-12 | |
US61/845,803 | 2013-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014100323A1 true WO2014100323A1 (en) | 2014-06-26 |
Family
ID=49917297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/076367 WO2014100323A1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Country Status (41)
Cited By (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015006731A1 (en) * | 2013-07-12 | 2015-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
WO2015006733A1 (en) * | 2013-07-12 | 2015-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
WO2015177537A1 (en) * | 2014-05-20 | 2015-11-26 | Cipla Limited | Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof |
US9216996B2 (en) | 2012-12-21 | 2015-12-22 | Gilead Sciences, Inc. | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
WO2015196116A1 (en) * | 2014-06-20 | 2015-12-23 | Gilead Sciences, Inc. | Sodium (2r, 5s, 13ar) -7, 9-dioxo-10- ( (2,4,6-trifluorobenzyl) carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13a-octahydro-2, 5-methanopyrido [1',2' : 4.5] pyrazino [2, 1-b] oxazepin-8-olate |
WO2015196137A1 (en) * | 2014-06-20 | 2015-12-23 | Gilead Sciences, Inc. | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5] pyrazino [2,1-b] [1,3] oxazepine-10-carboxamide |
WO2016027879A1 (en) * | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | Polycyclic pyridone derivative having integrase-inhibiting activity |
WO2016036759A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
WO2015195656A3 (en) * | 2014-06-20 | 2016-03-24 | Gilead Sciences ,Inc. | Synthesis of polycyclic-carbamoylpyridone compounds |
WO2016105534A1 (en) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Isoquinoline compounds for the treatment of hiv |
WO2016106237A1 (en) | 2014-12-23 | 2016-06-30 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
WO2016105564A1 (en) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Quinazoline derivatives used to treat hiv |
WO2016105532A1 (en) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Fused pyrimidine compounds for the treatment of hiv |
WO2016141092A1 (en) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
WO2016161382A1 (en) | 2015-04-02 | 2016-10-06 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
US9550765B2 (en) | 2013-01-15 | 2017-01-24 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
WO2017035230A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
WO2017059120A1 (en) | 2015-09-30 | 2017-04-06 | Gilead Sciences, Inc. | Compounds and combinations for the treatment of hiv |
WO2017083304A1 (en) | 2015-11-09 | 2017-05-18 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
US9676750B2 (en) | 2013-01-14 | 2017-06-13 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
WO2017106346A2 (en) | 2015-12-15 | 2017-06-22 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
US9688695B2 (en) | 2012-04-26 | 2017-06-27 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9862705B2 (en) | 2015-09-09 | 2018-01-09 | Incyte Corporation | Salts of a pim kinase inhibitor |
US9890162B2 (en) | 2014-07-14 | 2018-02-13 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
WO2018035359A1 (en) | 2016-08-19 | 2018-02-22 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2018042332A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
WO2018045144A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
WO2018064080A1 (en) | 2016-09-28 | 2018-04-05 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection |
WO2018064071A1 (en) | 2016-09-27 | 2018-04-05 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
US9949955B2 (en) | 2012-06-15 | 2018-04-24 | Glenmark Pharmaceuticals S.A. | Triazolone compounds as mPGES-1 inhibitors |
WO2018081292A1 (en) | 2016-10-27 | 2018-05-03 | Gilead Sciences, Inc. | Crystalline forms of darunavir free base, hydrate, solvates and salts |
US10000507B2 (en) | 2013-08-23 | 2018-06-19 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
WO2018144390A1 (en) | 2017-01-31 | 2018-08-09 | Gilead Sciences, Inc. | Crystalline forms of tenofovir alafenamide |
WO2018145021A1 (en) | 2017-02-06 | 2018-08-09 | Gilead Sciences, Inc. | Atazanavir (atv) analogues for treating hiv infections |
WO2018229798A1 (en) | 2017-06-13 | 2018-12-20 | Cipla Limited | Process for the preparation of bictegravir and intermediate thereof |
WO2018237148A1 (en) | 2017-06-21 | 2018-12-27 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
WO2019027920A1 (en) | 2017-08-01 | 2019-02-07 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections |
WO2019035904A1 (en) | 2017-08-17 | 2019-02-21 | Gilead Sciences, Inc. | Solid forms of an hiv capsid inhibitor |
WO2019035973A1 (en) | 2017-08-17 | 2019-02-21 | Gilead Sciences, Inc | Choline salt forms of an hiv capsid inhibitor |
US10246433B2 (en) | 2012-12-21 | 2019-04-02 | Pfizer Inc. | Aryl and heteroaryl fused lactams |
WO2019075291A1 (en) | 2017-10-13 | 2019-04-18 | Gilead Sciences, Inc. | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors |
WO2019084020A1 (en) | 2017-10-24 | 2019-05-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
WO2019113462A1 (en) | 2017-12-07 | 2019-06-13 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2019154634A1 (en) | 2018-02-09 | 2019-08-15 | Sandoz Ag | Crystalline form of bictegravir sodium |
WO2019159199A1 (en) | 2018-02-16 | 2019-08-22 | Cipla Limited | Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof |
WO2019161017A1 (en) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
WO2019193542A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides |
WO2019193533A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'2'-cyclic dinucleotides |
WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
US10479801B2 (en) | 2016-12-02 | 2019-11-19 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors |
WO2019230858A1 (en) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | Polycyclic carbamoylpyridone derivative |
WO2020004443A1 (en) | 2018-06-27 | 2020-01-02 | 国立大学法人北海道大学 | Arenavirus growth inhibitor comprising polycyclic carbamoyl pyridone derivative |
WO2020003151A1 (en) * | 2018-06-28 | 2020-01-02 | Honour Lab Limited | Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form |
WO2020010107A1 (en) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
WO2020018459A1 (en) | 2018-07-16 | 2020-01-23 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
RU2712275C2 (en) * | 2015-04-28 | 2020-01-28 | Сионоги Энд Ко., Лтд. | Substituted polycyclic pyridone derivatives and prodrugs thereof |
WO2020028272A1 (en) | 2018-07-30 | 2020-02-06 | Gilead Sciences, Inc. | Anti-hiv compounds |
US10570121B2 (en) | 2014-06-17 | 2020-02-25 | Pfizer Inc. | Substituted dihydroisoquinolinone compounds |
WO2020012408A3 (en) * | 2018-07-12 | 2020-03-05 | Laurus Labs Limited | A process for purification of protected polycyclic carbamoylpyridone derivatives |
RU2717101C1 (en) * | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Anellated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine-7-carboxamides - integrase inhibitors, methods for preparing and using thereof |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
WO2020092621A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
EP3653629A1 (en) | 2018-11-16 | 2020-05-20 | Sandoz AG | Acid addition salts of an integrase strand transfer inhibitor |
EP3664896A1 (en) | 2017-08-09 | 2020-06-17 | VIIV Healthcare Company | Combinations and uses and treatments thereof |
EP3664895A1 (en) | 2017-08-09 | 2020-06-17 | VIIV Healthcare Company | Combinations and uses and treatments thereof |
US10696657B2 (en) | 2018-02-16 | 2020-06-30 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
WO2020161744A1 (en) | 2019-02-07 | 2020-08-13 | Cipla Limited | Novel polymorphs of integrase inhibitor |
WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
WO2020214716A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | 2-imino-5-oxo-imidazolidine inhibitors of hiv protease |
WO2020214652A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020214663A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020214647A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
WO2020236753A1 (en) | 2019-05-21 | 2020-11-26 | Gilead Sciences, Inc. | Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021011544A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2021107066A1 (en) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
US11034668B2 (en) | 2011-07-06 | 2021-06-15 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
WO2021173522A1 (en) | 2020-02-24 | 2021-09-02 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
EP3693373A4 (en) * | 2017-10-06 | 2021-11-03 | Shionogi & Co., Ltd. | Method for stereoselectively producing substituted polycyclic pyridone derivative |
WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
CN113698420A (en) * | 2020-05-22 | 2021-11-26 | 上海迪赛诺生物医药有限公司 | Novel crystal form of bicalutavir sodium and preparation method thereof |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2021262990A1 (en) | 2020-06-25 | 2021-12-30 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
US11253524B2 (en) | 2018-01-19 | 2022-02-22 | Gilead Sciences, Inc. | Metabolites of bictegravir |
WO2022072520A1 (en) | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
WO2022087149A2 (en) | 2020-10-22 | 2022-04-28 | Gilead Sciences, Inc. | Interleukin-2-fc fusion proteins and methods of use |
CN114426540A (en) * | 2020-10-29 | 2022-05-03 | 上海拓界生物医药科技有限公司 | Pyrido [1,2-a ] pyrazine-1, 8-diketone prodrug derivatives, preparation method and application thereof |
WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
US11358711B2 (en) | 2019-06-20 | 2022-06-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors |
WO2022159387A1 (en) | 2021-01-19 | 2022-07-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
US11453669B2 (en) | 2018-05-31 | 2022-09-27 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11628181B2 (en) | 2014-12-26 | 2023-04-18 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2023102529A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
WO2023102239A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
WO2023196875A1 (en) | 2022-04-06 | 2023-10-12 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
EP3993797A4 (en) * | 2019-06-18 | 2023-10-25 | Laurus Labs Limited | Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof |
US11807625B2 (en) | 2019-11-26 | 2023-11-07 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
EP4281076A4 (en) * | 2021-01-22 | 2024-07-31 | Laurus Labs Ltd | Processes for purification of bictegravir intermediates |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016090545A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrate inhibitors |
CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109562113A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Loop coil degron body for target protein degradation |
WO2018005328A1 (en) * | 2016-06-27 | 2018-01-04 | Concert Pharmaceuticals, Inc. | Deuterated bictegravir |
CN108250215B (en) * | 2016-12-28 | 2022-04-19 | 华创合成制药股份有限公司 | Novel anti-HIV medicine, preparation method and application thereof |
CN106860414B (en) * | 2017-02-16 | 2019-12-24 | 江苏艾迪药业股份有限公司 | anti-HIV compound preparation and preparation method and application thereof |
CN106860464A (en) * | 2017-02-16 | 2017-06-20 | 江苏艾迪药业有限公司 | Pharmaceutical composition and application for combination antiviral therapy |
CN109020911B (en) * | 2018-04-16 | 2022-06-28 | 常州制药厂有限公司 | Intermediate for preparing bictegravir and preparation method thereof |
US11466031B2 (en) | 2018-04-26 | 2022-10-11 | Mylan Laboratories Limited | Polymorphic forms of bictegravir and its sodium salt |
CN110526930B (en) | 2018-05-23 | 2022-06-03 | 莫云芬 | anti-HIV (human immunodeficiency virus) sulfur-containing polycyclic-hydroxypyridone formamide analogue and application thereof |
EP3852761A1 (en) | 2018-09-19 | 2021-07-28 | Gilead Sciences, Inc. | Integrase inhibitors for the prevention of hiv |
SG11202104117WA (en) | 2018-10-22 | 2021-05-28 | Univ Nebraska | Antiviral prodrugs and nanoformulations thereof |
CN110229174A (en) * | 2019-05-22 | 2019-09-13 | 博诺康源(北京)药业科技有限公司 | The synthetic method of Bictegravir bulk pharmaceutical chemicals genotoxicity impurity |
CN110263404B (en) * | 2019-06-12 | 2023-03-21 | 江苏大学 | Method for calculating deposition characteristics of integrated prefabricated pump station based on DPM model |
CN110698473B (en) * | 2019-10-08 | 2020-12-18 | 浙江大学 | Piperazinone-hydroxypyridone-5-carboxyl compound, preparation and application |
US20230058677A1 (en) * | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Polycyclic pyridopyrazine derivative |
WO2022089562A1 (en) * | 2020-10-30 | 2022-05-05 | 上海拓界生物医药科技有限公司 | Use of inhibiting genetically defective hiv virus |
WO2023006087A1 (en) * | 2021-07-30 | 2023-02-02 | 南京明德新药研发有限公司 | Macrocyclic pyridone compound and application thereof |
CN114605437A (en) * | 2022-04-01 | 2022-06-10 | 遵义医科大学 | Synthesis process for preparing three telaprevir medicaments by continuous one-pot method |
WO2023248240A1 (en) | 2022-06-21 | 2023-12-28 | Mylan Laboratories Limited | Polymorphic forms of bictegravir sodium |
WO2024061257A1 (en) * | 2022-09-20 | 2024-03-28 | 吉斯凯(苏州)制药有限公司 | Polycyclic n-heterocyclic ketone compound and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006116764A1 (en) * | 2005-04-28 | 2006-11-02 | Smithkline Beecham Corporation | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP2412709A1 (en) * | 2009-03-26 | 2012-02-01 | Shionogi & Co., Ltd. | Process for producing pyrone and pyridone derivatives |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE788516A (en) | 1971-09-10 | 1973-03-07 | Lonza Ag | METHOD OF MANUFACTURING ALCOXYACETYLACETIC ESTERS |
GB1528382A (en) | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
DE2658401A1 (en) | 1976-12-23 | 1978-07-06 | Merck Patent Gmbh | CYCLOPENTAN-1-AMINE, METHOD FOR THE PRODUCTION THEREOF AND AGENTS CONTAINING THESE COMPOUNDS |
US4575694A (en) | 1984-03-05 | 1986-03-11 | Allied Corporation | Coaxial connector |
DE3900735A1 (en) | 1989-01-12 | 1990-07-26 | Hoechst Ag | NEW MULTI-FUNCTIONAL (ALPHA) -DIAZO- (BETA) -KETOESTERS, METHOD FOR THEIR PRODUCTION AND USE THEREOF |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
DE4014649A1 (en) | 1990-05-08 | 1991-11-14 | Hoechst Ag | NEW MULTIFUNCTIONAL CONNECTIONS WITH (ALPHA) -DIAZO-SS-KETOESTER AND SULPHONIC ACID UNIT UNITS, METHOD FOR THEIR PRODUCTION AND USE THEREOF |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
SE9702772D0 (en) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
AU1403099A (en) | 1997-11-14 | 1999-06-07 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
PL347591A1 (en) | 1998-11-09 | 2002-04-08 | Gastrin and cholecystokinin receptor ligands | |
GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
CZ20012160A3 (en) | 1998-12-25 | 2001-10-17 | Shionogi & Co., Ltd. | Aromatic heterocycle compounds having HIV integrase inhibiting activities |
WO2001095905A1 (en) | 2000-06-14 | 2001-12-20 | Shionogi & Co., Ltd. | Inhibitor for enzyme having two divalent metal ions as active centers |
CA2425395C (en) * | 2000-10-12 | 2009-06-02 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
ES2587564T1 (en) | 2001-08-10 | 2016-10-25 | Shionogi & Co., Ltd. | Antiviral agent |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US20050004180A1 (en) | 2001-10-03 | 2005-01-06 | ZOU Dong | Pyrrolidinone derivatives |
PT1441735E (en) | 2001-10-26 | 2006-06-30 | Istituto Di Ricerche Di B Mo P | HIV INTEGRASE INHIBITORS BASED ON N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE |
AU2003248872A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
WO2004046115A1 (en) | 2002-11-20 | 2004-06-03 | Japan Tobacco Inc. | 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors |
WO2004064846A1 (en) | 2003-01-14 | 2004-08-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
WO2005074513A2 (en) | 2004-01-30 | 2005-08-18 | Merck & Co., Inc. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integrase inhibitors |
BRPI0507628A (en) | 2004-02-11 | 2007-07-03 | Smithkline Beecham Corp | pharmaceutically acceptable compound or salt thereof, method of treating a viral infection in a human, use of a compound pharmaceutical composition, and process for preparing a compound |
US7619086B2 (en) | 2004-03-09 | 2009-11-17 | Merck & Co., Inc. | HIV integrase inhibitors |
EP1755586A2 (en) | 2004-04-29 | 2007-02-28 | The Regents of the University of California | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
WO2005110399A2 (en) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Zinc-binding groups for metalloprotein inhibitors |
JP4824673B2 (en) | 2004-05-07 | 2011-11-30 | メルク・シャープ・エンド・ドーム・コーポレイション | HIV integrase inhibitor |
US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
EP1750708A1 (en) * | 2004-05-17 | 2007-02-14 | Tibotec Pharmaceuticals Ltd. | Combinations of substituted 1-phenyl-1,5-dihydro-pyrido- [3,2-b] indol-2-ones and other hiv inhibitors |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
WO2005113509A1 (en) | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
EP2332538A1 (en) | 2004-05-21 | 2011-06-15 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
WO2006030807A1 (en) | 2004-09-15 | 2006-03-23 | Shionogi & Co., Ltd. | Carbamoylpyridone derivative having hiv integrase inhibitory activity |
JP2006118669A (en) | 2004-10-25 | 2006-05-11 | Sanoh Industrial Co Ltd | Resin tube |
CA2634499A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
ATE516026T1 (en) | 2005-02-21 | 2011-07-15 | Shionogi & Co | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE WITH HIV INTEGRASE INHIBITING EFFECT |
US20070072831A1 (en) | 2005-05-16 | 2007-03-29 | Gilead Sciences, Inc. | Integrase inhibitor compounds |
TWI471145B (en) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | Unitary pharmaceutical dosage form |
AU2006272521A1 (en) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of HIV |
EA200801144A1 (en) | 2005-10-27 | 2008-10-30 | Сионоги Энд Ко., Лтд. | POLYCYCLIC CARBAMOYLPYRIDON DERIVATIVE, HAS INHIBITOR ACTIVITY WITH RESPECT TO HIV INTEGRASES |
KR20160074018A (en) | 2005-12-30 | 2016-06-27 | 길리애드 사이언시즈, 인코포레이티드 | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
JP2009525261A (en) | 2006-02-01 | 2009-07-09 | 日本たばこ産業株式会社 | 6- (3-Chloro-2-fluorobenzyl) -1-[(2S) -1-hydroxy-3-methylbutan-2-yl] -7-methoxy-4-oxo for the treatment of retroviral infections Use of -1,4-dihydroquinoline-3-carboxylic acid or a salt thereof |
CA2645119C (en) | 2006-03-06 | 2012-01-24 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
CN101437801B (en) | 2006-03-06 | 2013-02-06 | 日本烟草产业株式会社 | Process for production of 4-oxoquinoline compound |
US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
MX2009000661A (en) | 2006-07-19 | 2009-03-27 | Univ Georgia Res Found | Pyridinone diketo acids: inhibitors of hiv replication in combination therapy. |
NZ575542A (en) | 2006-09-12 | 2012-03-30 | Gilead Sciences Inc | Process and intermediates for preparing 4-oxoquinolone integrase inhibitors |
AU2007313293A1 (en) | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | HIV integrase inhibitors |
SG183059A1 (en) | 2007-02-23 | 2012-08-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
CN103356622A (en) | 2007-06-29 | 2013-10-23 | 吉里德科学公司 | Therapeutic compositions and the use thereof |
WO2009006199A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
US20090258939A1 (en) | 2007-07-31 | 2009-10-15 | Wendye Robbins | Pyrone analog compositions and methods |
AR068403A1 (en) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | PROCESS AND INTERMEDIARIES FOR THE PREPARATION OF INTEGRASA INHIBITORS |
NZ585226A (en) | 2007-11-16 | 2012-08-31 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
GB0803019D0 (en) | 2008-02-19 | 2008-03-26 | Btg Int Ltd | Fluorinated compounds |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US20100272811A1 (en) | 2008-07-23 | 2010-10-28 | Alkermes,Inc. | Complex of trospium and pharmaceutical compositions thereof |
KR101772610B1 (en) | 2008-07-25 | 2017-09-12 | 비이브 헬쓰케어 컴퍼니 | Chemical compounds |
WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
EP2330902B1 (en) | 2008-07-25 | 2012-11-14 | GlaxoSmithKline LLC | Chemical compounds |
WO2010011812A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010068262A1 (en) | 2008-12-11 | 2010-06-17 | Glaxosmithkline Llc | Processes and intermediates for carbamoylpyridone hiv integrase inhibitors |
MX351942B (en) | 2008-12-11 | 2017-11-03 | Shionogi & Co | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates. |
US9938268B2 (en) | 2008-12-17 | 2018-04-10 | Merck Patent Gmbh | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
AP3250A (en) | 2009-02-06 | 2015-05-31 | Gilead Sciences Inc | Tablets for combination therapy |
US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
TR201808501T4 (en) | 2009-06-15 | 2018-07-23 | Shionogi & Co | Substituted polycyclic carbamoylpyridone derivative. |
KR101280198B1 (en) | 2009-09-02 | 2013-06-28 | 이화여자대학교 산학협력단 | pyrazole derivatives, preparation thereof and composition comprising the same for prevention and treatment of osteoporosis |
US20120295898A1 (en) | 2010-01-27 | 2012-11-22 | Mark Richard Underwood | Antiviral Therapy |
RU2012140961A (en) | 2010-02-26 | 2014-04-10 | Джапан Тобакко Инк. | DERIVATIVE OF 1,3,4,8-TETRAHYDRO-2H-PYRIDO [1,2-a] PYRAZINE AND ITS APPLICATION AS AN HIV INTEGRASE INHIBITOR |
TWI582097B (en) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | Process for preparing carbamoylpyridone derivatives and intermediates |
US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
TWI458711B (en) | 2010-07-02 | 2014-11-01 | Gilead Sciences Inc | Therapeutic compounds |
NZ604598A (en) | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | Naphth-2-ylacetic acid derivatives to treat aids |
US20130210809A1 (en) | 2010-07-14 | 2013-08-15 | Christelle Boléa | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
CN106046022B (en) | 2010-08-05 | 2018-06-19 | 盐野义制药株式会社 | The manufacturing method of compound with hiv integrase inhibitory activity |
WO2012039414A1 (en) | 2010-09-24 | 2012-03-29 | 塩野義製薬株式会社 | Substituted polycyclic carbamoyl pyridone derivative prodrug |
SG10201912527XA (en) | 2010-11-19 | 2020-02-27 | Gilead Sciences Inc | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
WO2012106534A2 (en) | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
WO2012145728A1 (en) | 2011-04-21 | 2012-10-26 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
WO2012151361A1 (en) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
US9121496B2 (en) | 2011-06-29 | 2015-09-01 | Arvinmeritor Technology, Llc | Drive axle system and a method of control |
AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
CN102863512B (en) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | Antiviral compound |
RS56667B1 (en) | 2011-07-07 | 2018-03-30 | Janssen Sciences Ireland Uc | Darunavir combination formulations |
EP2742051B1 (en) | 2011-09-14 | 2016-10-12 | Mapi Pharma Limited | Amorpous form of the dolutegravir sodium salt |
WO2013054862A1 (en) | 2011-10-12 | 2013-04-18 | 塩野義製薬株式会社 | Polycyclic pyridone derivative having integrase-inhibiting activity |
EP2804864B1 (en) | 2011-12-12 | 2017-09-06 | Bayer Intellectual Property GmbH | Amino-substituted imidazopyridazines |
US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
US20150166520A1 (en) | 2012-07-20 | 2015-06-18 | Merck Sharp & Dohme Corp. | Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection |
EP2877469A4 (en) | 2012-07-25 | 2016-04-06 | Merck Sharp & Dohme | Substituted naphthyridinedione derivatives as hiv integrase inhibitors |
EA026089B1 (en) | 2012-08-03 | 2017-02-28 | Джилид Сайэнс, Инк. | Process and intermediates for preparing integrase inhibitors |
BR112015009850A2 (en) | 2012-11-08 | 2017-07-11 | Bristol Myers Squibb Co | heteroaryl substituted pyridyl compounds useful as kinase modulators |
EA201590862A1 (en) | 2012-12-14 | 2016-05-31 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | PHARMACEUTICAL COMPOSITIONS |
WO2014099586A1 (en) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
EP2934482A4 (en) | 2012-12-21 | 2016-07-20 | Merck Sharp & Dohme | Gastro-retentive formulations |
US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CA2893843C (en) * | 2012-12-21 | 2018-09-04 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
AR094311A1 (en) | 2012-12-27 | 2015-07-22 | Japan Tobacco Inc | DERIVATIVES OF TETRAHYDROESPIRO-CICLOPROPIL-PIRIDO [1,2-A] PIRAZINA INHIBITORS OF HIV INTEGRASE |
US9493479B2 (en) | 2013-04-16 | 2016-11-15 | Merck Sharp & Dohme Corp. | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors |
US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
PL3019503T3 (en) | 2013-07-12 | 2018-01-31 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
NO2865735T3 (en) | 2013-07-12 | 2018-07-21 | ||
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
US9861620B2 (en) | 2013-09-27 | 2018-01-09 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as HIV integrase inhibitors |
WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
IN2014CH00247A (en) | 2014-01-21 | 2015-08-14 | Laurus Labs Private Ltd | |
WO2015138933A1 (en) | 2014-03-13 | 2015-09-17 | Assia Chemical Industries Ltd. | Solid state forms of dolutegravir sodium |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
NO2717902T3 (en) | 2014-06-20 | 2018-06-23 | ||
TWI744723B (en) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | Synthesis of polycyclic-carbamoylpyridone compounds |
AU2015287773B2 (en) * | 2014-07-11 | 2018-03-29 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
TWI738321B (en) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
EP3277691B1 (en) | 2015-04-02 | 2019-01-30 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
PT4070788T (en) | 2015-06-30 | 2023-06-06 | Gilead Sciences Inc | Pharmaceutical formulations |
CA2921336A1 (en) | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
CN113546052A (en) | 2015-11-09 | 2021-10-26 | 吉利德科学公司 | Therapeutic compositions for the treatment of human immunodeficiency virus |
-
2013
- 2013-12-19 CA CA2893843A patent/CA2893843C/en active Active
- 2013-12-19 TW TW110146626A patent/TWI815245B/en active
- 2013-12-19 EA EA201591027A patent/EA030003B1/en active Protection Beyond IP Right Term
- 2013-12-19 MX MX2015008009A patent/MX344879B/en active IP Right Grant
- 2013-12-19 HU HUE15201519A patent/HUE046559T2/en unknown
- 2013-12-19 TW TW102147242A patent/TWI642669B/en active
- 2013-12-19 EP EP22178867.2A patent/EP4122935A1/en active Pending
- 2013-12-19 KR KR1020227001078A patent/KR102406288B1/en active IP Right Grant
- 2013-12-19 JP JP2015549669A patent/JP6028105B2/en active Active
- 2013-12-19 DK DK19185121.1T patent/DK3608325T3/en active
- 2013-12-19 RS RS20160407A patent/RS54873B1/en unknown
- 2013-12-19 PE PE2016000694A patent/PE20170528A1/en unknown
- 2013-12-19 MX MX2017000362A patent/MX357940B/en unknown
- 2013-12-19 PE PE2015001036A patent/PE20151499A1/en active IP Right Grant
- 2013-12-19 WO PCT/US2013/076367 patent/WO2014100323A1/en active Application Filing
- 2013-12-19 MD MDA20170067A patent/MD4754C1/en active IP Right Grant
- 2013-12-19 MY MYPI2016001880A patent/MY191741A/en unknown
- 2013-12-19 PT PT191851211T patent/PT3608325T/en unknown
- 2013-12-19 PT PT152015194T patent/PT3067358T/en unknown
- 2013-12-19 PT PT138159371T patent/PT2822954E/en unknown
- 2013-12-19 UA UAA201612380A patent/UA123572C2/en unknown
- 2013-12-19 LT LTEP19185121.1T patent/LT3608325T/en unknown
- 2013-12-19 MY MYPI2015001580A patent/MY164352A/en unknown
- 2013-12-19 KR KR1020217012463A patent/KR102351912B1/en active IP Right Grant
- 2013-12-19 UY UY35213A patent/UY35213A/en not_active Application Discontinuation
- 2013-12-19 US US14/133,858 patent/US9216996B2/en active Active
- 2013-12-19 TW TW107127529A patent/TWI693224B/en active
- 2013-12-19 ME MEP-2016-93A patent/ME02400B/en unknown
- 2013-12-19 HU HUE19185121A patent/HUE059688T2/en unknown
- 2013-12-19 SI SI201332004T patent/SI3608325T1/en unknown
- 2013-12-19 KR KR1020197031864A patent/KR102120875B1/en active IP Right Grant
- 2013-12-19 BR BR112015014714-3A patent/BR112015014714B1/en active IP Right Grant
- 2013-12-19 UA UAA201506209A patent/UA114351C2/en unknown
- 2013-12-19 CN CN201380073134.XA patent/CN104995198B/en active Active
- 2013-12-19 EA EA201890236A patent/EA037633B1/en unknown
- 2013-12-19 ES ES13815937.1T patent/ES2577283T3/en active Active
- 2013-12-19 DK DK13815937.1T patent/DK2822954T3/en active
- 2013-12-19 SG SG11201504857SA patent/SG11201504857SA/en unknown
- 2013-12-19 SI SI201330197A patent/SI2822954T1/en unknown
- 2013-12-19 DK DK15201519T patent/DK3067358T3/en active
- 2013-12-19 BR BR122015029881-4A patent/BR122015029881B1/en active IP Right Grant
- 2013-12-19 CN CN202010188107.9A patent/CN111303152B/en active Active
- 2013-12-19 ES ES19185121T patent/ES2926068T3/en active Active
- 2013-12-19 CN CN202310322212.0A patent/CN116640140A/en active Pending
- 2013-12-19 CN CN201711080644.6A patent/CN107674086B/en active Active
- 2013-12-19 EP EP13815937.1A patent/EP2822954B1/en active Active
- 2013-12-19 HR HRP20220899TT patent/HRP20220899T1/en unknown
- 2013-12-19 AU AU2013361401A patent/AU2013361401C1/en active Active
- 2013-12-19 NZ NZ709260A patent/NZ709260A/en unknown
- 2013-12-19 HU HUE13815937A patent/HUE028284T2/en unknown
- 2013-12-19 KR KR1020237014240A patent/KR20230061576A/en not_active Application Discontinuation
- 2013-12-19 KR KR1020227018650A patent/KR102527797B1/en active IP Right Grant
- 2013-12-19 KR KR1020177016697A patent/KR102040007B1/en active IP Right Grant
- 2013-12-19 TW TW112109785A patent/TWI830624B/en active
- 2013-12-19 KR KR1020157019194A patent/KR101770048B1/en active IP Right Grant
- 2013-12-19 CR CR20170279A patent/CR20170279A/en unknown
- 2013-12-19 PL PL13815937.1T patent/PL2822954T3/en unknown
- 2013-12-19 PH PH12019501848A patent/PH12019501848A1/en unknown
- 2013-12-19 KR KR1020207015960A patent/KR102246963B1/en active IP Right Grant
- 2013-12-19 NZ NZ718708A patent/NZ718708A/en unknown
- 2013-12-19 PL PL15201519T patent/PL3067358T3/en unknown
- 2013-12-19 SI SI201331609T patent/SI3067358T1/en unknown
- 2013-12-19 AP AP2015008510A patent/AP2015008510A0/en unknown
- 2013-12-19 EP EP15201519.4A patent/EP3067358B1/en active Active
- 2013-12-19 EP EP19185121.1A patent/EP3608325B1/en active Active
- 2013-12-19 LT LT15201519T patent/LT3067358T/en unknown
- 2013-12-19 MD MDA20200093A patent/MD4841B1/en not_active IP Right Cessation
- 2013-12-19 CA CA3012242A patent/CA3012242C/en active Active
- 2013-12-19 ES ES15201519T patent/ES2753548T3/en active Active
- 2013-12-19 TW TW109111537A patent/TWI752457B/en active
- 2013-12-19 PL PL19185121.1T patent/PL3608325T3/en unknown
- 2013-12-19 CA CA3131094A patent/CA3131094A1/en active Pending
- 2013-12-19 AR ARP130104930A patent/AR094197A1/en active IP Right Grant
- 2013-12-19 MD MDA20150064A patent/MD4736C1/en active IP Right Grant
-
2015
- 2015-06-10 IL IL239316A patent/IL239316A/en active IP Right Grant
- 2015-06-18 CL CL2015001756A patent/CL2015001756A1/en unknown
- 2015-06-18 MX MX2020003055A patent/MX2020003055A/en unknown
- 2015-06-18 MX MX2022013596A patent/MX2022013596A/en unknown
- 2015-06-22 PH PH12015501445A patent/PH12015501445A1/en unknown
- 2015-06-22 HK HK15105909.2A patent/HK1205124A1/en unknown
- 2015-07-17 CR CR20150380A patent/CR20150380A/en unknown
- 2015-07-31 US US14/815,504 patent/US9663528B2/en active Active
- 2015-10-26 ZA ZA2015/07997A patent/ZA201507997B/en unknown
-
2016
- 2016-02-29 PH PH12016500389A patent/PH12016500389B1/en unknown
- 2016-04-11 CL CL2016000837A patent/CL2016000837A1/en unknown
- 2016-04-21 HK HK18110106.0A patent/HK1250711A1/en unknown
- 2016-04-21 HK HK16104629.3A patent/HK1216643A1/en unknown
- 2016-05-20 HR HRP20160544TT patent/HRP20160544T1/en unknown
- 2016-05-23 IL IL245780A patent/IL245780B/en active IP Right Grant
- 2016-05-30 CY CY20161100472T patent/CY1117570T1/en unknown
- 2016-06-01 SM SM201600157T patent/SMT201600157B/en unknown
- 2016-06-21 JP JP2016122743A patent/JP6411409B2/en active Active
- 2016-08-17 IL IL247311A patent/IL247311A0/en unknown
- 2016-11-11 US US15/349,934 patent/US9732092B2/en active Active
- 2016-11-24 AU AU2016262722A patent/AU2016262722B2/en active Active
-
2017
- 2017-05-11 CL CL2017001191A patent/CL2017001191A1/en unknown
- 2017-05-18 US US15/599,151 patent/US10035809B2/en active Active
-
2018
- 2018-06-25 US US16/017,371 patent/US10689399B2/en active Active
- 2018-08-17 LU LU00083C patent/LUC00083I2/en unknown
- 2018-08-21 LT LTPA2018511C patent/LTC2822954I2/en unknown
- 2018-08-22 NL NL300947C patent/NL300947I2/en unknown
- 2018-08-23 HU HUS1800035C patent/HUS1800035I1/en unknown
- 2018-08-23 CY CY2018022C patent/CY2018022I1/en unknown
- 2018-09-19 AU AU2018232957A patent/AU2018232957B2/en active Active
- 2018-09-26 JP JP2018179844A patent/JP6571256B2/en active Active
-
2019
- 2019-02-22 ZA ZA2019/03516A patent/ZA201903516B/en unknown
- 2019-08-07 JP JP2019145317A patent/JP6933690B2/en active Active
- 2019-10-29 HR HRP20191957TT patent/HRP20191957T1/en unknown
- 2019-11-05 CY CY20191101151T patent/CY1122246T1/en unknown
-
2020
- 2020-05-01 AU AU2020202914A patent/AU2020202914B2/en active Active
- 2020-05-06 US US16/868,119 patent/US11548901B2/en active Active
- 2020-05-28 IL IL274988A patent/IL274988A/en unknown
-
2021
- 2021-08-19 JP JP2021134172A patent/JP7301918B2/en active Active
- 2021-08-23 AU AU2021221427A patent/AU2021221427B2/en active Active
-
2023
- 2023-06-21 JP JP2023101636A patent/JP2023134483A/en active Pending
- 2023-12-30 AU AU2023286038A patent/AU2023286038A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006116764A1 (en) * | 2005-04-28 | 2006-11-02 | Smithkline Beecham Corporation | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP2412709A1 (en) * | 2009-03-26 | 2012-02-01 | Shionogi & Co., Ltd. | Process for producing pyrone and pyridone derivatives |
Cited By (306)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11034668B2 (en) | 2011-07-06 | 2021-06-15 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
US10047103B2 (en) | 2012-04-26 | 2018-08-14 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation |
US9688695B2 (en) | 2012-04-26 | 2017-06-27 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation |
US10822343B2 (en) | 2012-04-26 | 2020-11-03 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation |
US10428077B2 (en) | 2012-04-26 | 2019-10-01 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation |
US10391083B2 (en) | 2012-06-15 | 2019-08-27 | Glenmark Pharmaceuticals S.A | Triazolone compounds as MPGES-1 inhibitors |
US10821100B2 (en) | 2012-06-15 | 2020-11-03 | Ichnos Sciences SA | Triazolone compounds as mPGES-1 inhibitors |
US9949955B2 (en) | 2012-06-15 | 2018-04-24 | Glenmark Pharmaceuticals S.A. | Triazolone compounds as mPGES-1 inhibitors |
US10246433B2 (en) | 2012-12-21 | 2019-04-02 | Pfizer Inc. | Aryl and heteroaryl fused lactams |
US9663528B2 (en) | 2012-12-21 | 2017-05-30 | Gilead Sciences, Inc. | Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections |
US10689399B2 (en) | 2012-12-21 | 2020-06-23 | Gilead Sciences, Inc. | Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections |
US9216996B2 (en) | 2012-12-21 | 2015-12-22 | Gilead Sciences, Inc. | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
US9732092B2 (en) | 2012-12-21 | 2017-08-15 | Gilead Sciences, Inc. | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections |
US10035809B2 (en) | 2012-12-21 | 2018-07-31 | Gilead Sciences, Inc. | Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections |
US11548901B2 (en) | 2012-12-21 | 2023-01-10 | Gilead Sciences, Inc. | Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections |
US9676750B2 (en) | 2013-01-14 | 2017-06-13 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
US11229631B2 (en) | 2013-01-15 | 2022-01-25 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
US10517858B2 (en) | 2013-01-15 | 2019-12-31 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors |
US9849120B2 (en) | 2013-01-15 | 2017-12-26 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
US10265307B2 (en) | 2013-01-15 | 2019-04-23 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
US10828290B2 (en) | 2013-01-15 | 2020-11-10 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
US9550765B2 (en) | 2013-01-15 | 2017-01-24 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
JP2016525102A (en) * | 2013-07-12 | 2016-08-22 | ギリアード サイエンシス インコーポレーテッド | Polycyclic carbamoylpyridone compounds and their use for treating HIV infection |
US11883397B2 (en) | 2013-07-12 | 2024-01-30 | Gilead Sciences, Inc. | Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections |
EP3252053A1 (en) * | 2013-07-12 | 2017-12-06 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
AU2014286993B2 (en) * | 2013-07-12 | 2018-10-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections |
US10668064B2 (en) | 2013-07-12 | 2020-06-02 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US10456395B2 (en) | 2013-07-12 | 2019-10-29 | Gilead Sciences, Inc. | Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections |
AU2018236731B2 (en) * | 2013-07-12 | 2020-02-27 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections |
US9421214B2 (en) | 2013-07-12 | 2016-08-23 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
EP3252058A1 (en) * | 2013-07-12 | 2017-12-06 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
US9458159B2 (en) | 2013-07-12 | 2016-10-04 | Gilead Sciences, Inc. | Substituted pyrido[1′,2′:4,5]pyrazino[1,2-a]azepines for treating viral infections |
WO2015006733A1 (en) * | 2013-07-12 | 2015-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
US11213523B2 (en) | 2013-07-12 | 2022-01-04 | Gilead Sciences, Inc. | Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections |
US9700554B2 (en) | 2013-07-12 | 2017-07-11 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
WO2015006731A1 (en) * | 2013-07-12 | 2015-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
AU2018236701B2 (en) * | 2013-07-12 | 2020-04-30 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections |
JP2016527217A (en) * | 2013-07-12 | 2016-09-08 | ギリアード サイエンシス インコーポレーテッド | Polycyclic carbamoylpyridone compounds and their use for treating HIV infection |
US10000507B2 (en) | 2013-08-23 | 2018-06-19 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
WO2015177537A1 (en) * | 2014-05-20 | 2015-11-26 | Cipla Limited | Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof |
US10570121B2 (en) | 2014-06-17 | 2020-02-25 | Pfizer Inc. | Substituted dihydroisoquinolinone compounds |
US10975096B2 (en) | 2014-06-20 | 2021-04-13 | Gilead Sciences, Inc. | Synthesis of polycyclic-carbamoylpyridone compounds |
EP3564244A1 (en) | 2014-06-20 | 2019-11-06 | Gilead Sciences, Inc. | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide |
KR20190049937A (en) * | 2014-06-20 | 2019-05-09 | 길리애드 사이언시즈, 인코포레이티드 | Synthesis of polycyclic-carbamoylpyridone compounds |
WO2015196116A1 (en) * | 2014-06-20 | 2015-12-23 | Gilead Sciences, Inc. | Sodium (2r, 5s, 13ar) -7, 9-dioxo-10- ( (2,4,6-trifluorobenzyl) carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13a-octahydro-2, 5-methanopyrido [1',2' : 4.5] pyrazino [2, 1-b] oxazepin-8-olate |
WO2015196137A1 (en) * | 2014-06-20 | 2015-12-23 | Gilead Sciences, Inc. | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5] pyrazino [2,1-b] [1,3] oxazepine-10-carboxamide |
EP4309736A3 (en) * | 2014-06-20 | 2024-05-08 | Gilead Sciences, Inc. | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide |
JP2017521398A (en) * | 2014-06-20 | 2017-08-03 | ギリアード サイエンシス インコーポレーテッド | Synthesis of polycyclic carbamoylpyridone compounds. |
EP4309736A2 (en) | 2014-06-20 | 2024-01-24 | Gilead Sciences, Inc. | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide |
US11202780B2 (en) | 2014-06-20 | 2021-12-21 | Gilead Sciences, Inc. | Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
EP3157932B1 (en) | 2014-06-20 | 2018-01-10 | Gilead Sciences, Inc. | Sodium (2r, 5s, 13ar) -7, 9-dioxo-10- ( (2,4,6-trifluorobenzyl) carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13a-octahydro-2, 5-methanopyrido [1',2' : 4.5]pyrazino [2, 1-b]oxazepin-8-olate |
US10385067B2 (en) | 2014-06-20 | 2019-08-20 | Gilead Sciences, Inc. | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate |
US9708342B2 (en) | 2014-06-20 | 2017-07-18 | Gilead Sciences, Inc. | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate |
MD20170006A2 (en) * | 2014-06-20 | 2017-06-30 | Gilead Sciences, Inc. | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate |
US9682084B2 (en) | 2014-06-20 | 2017-06-20 | Gilead Sciences, Inc. | Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
AU2018217236B2 (en) * | 2014-06-20 | 2020-03-05 | Gilead Sciences, Inc. | Synthesis of polycyclic-carbamoylpyridone compounds |
EP3527573A1 (en) * | 2014-06-20 | 2019-08-21 | Gilead Sciences, Inc. | Synthesis of polycyclic-carbamoylpyridone compounds |
WO2015195656A3 (en) * | 2014-06-20 | 2016-03-24 | Gilead Sciences ,Inc. | Synthesis of polycyclic-carbamoylpyridone compounds |
EA034169B1 (en) * | 2014-06-20 | 2020-01-14 | Джилид Сайэнс, Инк. | Synthesis of polycyclic carbamoylpyridone compounds |
CN114394983A (en) * | 2014-06-20 | 2022-04-26 | 吉利德科学公司 | Synthesis of polycyclic carbamoylpyridone compounds |
AU2018203175B2 (en) * | 2014-06-20 | 2020-01-02 | Gilead Sciences, Inc. | Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate |
EA030967B1 (en) * | 2014-06-20 | 2018-10-31 | Джилид Сайэнс, Инк. | SODIUM (2R,5S,13aR)-7,9-DIOXO-10-((2,4,6-TRIFLUOROBENZYL)CARBAMOYL)-2,3,4,5,7,9,13,13a-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-b][1,3]OXAZEPIN-8-OLATE |
US10098886B2 (en) | 2014-06-20 | 2018-10-16 | Gilead Sciences, Inc. | Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13A- octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide |
US10519168B2 (en) | 2014-06-20 | 2019-12-31 | Gilead Sciences, Inc. | Synthesis of polycyclic-carbamoylpyridone compounds |
EP3321270A1 (en) | 2014-06-20 | 2018-05-16 | Gilead Sciences, Inc. | Sodium (2r, 5s, 13ar) -7, 9-dioxo-10- ( (2,4,6-trifluorobenzyl) carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13a-octahydro-2, 5-methanopyrido [1',2' : 4.5] pyrazino [2, 1-b] oxazepin-8-olate |
CN110317212B (en) * | 2014-06-20 | 2022-10-21 | 吉利德科学公司 | Synthesis of polycyclic carbamoylpyridone compounds |
AU2015276860B2 (en) * | 2014-06-20 | 2018-05-31 | Gilead Sciences, Inc. | Sodium (2r, 5s, 13ar) -7, 9-dioxo-10- ( (2,4,6-trifluorobenzyl) carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13a-octahydro-2, 5-methanopyrido [1',2' : 4.5] pyrazino [2, 1-b][1,3]oxazepin-8-olate |
CN106459085A (en) * | 2014-06-20 | 2017-02-22 | 吉利德科学公司 | Sodium (2r, 5s, 13ar) -7, 9-dioxo-10- ( (2,4,6-trifluorobenzyl) carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13a-octahydro-2, 5-methanopyrido [1',2' : 4.5] pyrazino [2, 1-b] oxazepin-8-olate |
KR101899803B1 (en) | 2014-06-20 | 2018-09-20 | 길리애드 사이언시즈, 인코포레이티드 | Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4.5]pyrazino[2,1-b]oxazepin-8-olate |
AU2015277312B2 (en) * | 2014-06-20 | 2018-08-30 | Gilead Sciences, Inc. | Synthesis of polycyclic-carbamoylpyridone compounds |
KR102159892B1 (en) | 2014-06-20 | 2020-09-25 | 길리애드 사이언시즈, 인코포레이티드 | Synthesis of polycyclic-carbamoylpyridone compounds |
EP3783001A1 (en) * | 2014-06-20 | 2021-02-24 | Gilead Sciences, Inc. | Synthesis of polycyclic-carbamoylpyridone compounds |
CN110317212A (en) * | 2014-06-20 | 2019-10-11 | 吉利德科学公司 | The synthesis of polycyclic carbamoylpyridone compound |
US9890162B2 (en) | 2014-07-14 | 2018-02-13 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016027879A1 (en) * | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | Polycyclic pyridone derivative having integrase-inhibiting activity |
US10202404B2 (en) | 2014-08-22 | 2019-02-12 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
JPWO2016027879A1 (en) * | 2014-08-22 | 2017-06-01 | 塩野義製薬株式会社 | Polycyclic pyridone derivatives having integrase inhibitory activity |
JP2021042237A (en) * | 2014-08-22 | 2021-03-18 | 塩野義製薬株式会社 | Polycyclic pyridone derivative having integrase inhibitory activity |
EP3757105A2 (en) | 2014-08-22 | 2020-12-30 | Shionogi & Co., Ltd | Polycyclic pyridone derivative having integrase inhibitory activity |
US10011613B2 (en) | 2014-08-22 | 2018-07-03 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
WO2016036759A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
WO2016106237A1 (en) | 2014-12-23 | 2016-06-30 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR102240584B1 (en) | 2014-12-23 | 2021-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR102020004B1 (en) | 2014-12-23 | 2019-09-06 | 길리애드 사이언시즈, 인코포레이티드 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR101978167B1 (en) | 2014-12-23 | 2019-05-14 | 길리애드 사이언시즈, 인코포레이티드 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR20190052172A (en) * | 2014-12-23 | 2019-05-15 | 길리애드 사이언시즈, 인코포레이티드 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR20190104458A (en) * | 2014-12-23 | 2019-09-09 | 길리애드 사이언시즈, 인코포레이티드 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US9795602B2 (en) | 2014-12-23 | 2017-10-24 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
JP2018172437A (en) * | 2014-12-23 | 2018-11-08 | ギリアード サイエンシーズ, インコーポレイテッド | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
JP2017538713A (en) * | 2014-12-23 | 2017-12-28 | ギリアード サイエンシーズ, インコーポレイテッド | Polycyclic carbamoylpyridone compounds and their pharmaceutical use |
EP3388431A1 (en) | 2014-12-23 | 2018-10-17 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR20170097168A (en) * | 2014-12-23 | 2017-08-25 | 길리애드 사이언시즈, 인코포레이티드 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CN107108643A (en) * | 2014-12-23 | 2017-08-29 | 吉利德科学公司 | Polycyclic carbonic acyl radical pyridinone compounds and its medicinal usage |
US9522912B2 (en) | 2014-12-23 | 2016-12-20 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US10646486B2 (en) | 2014-12-23 | 2020-05-12 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CN111454273A (en) * | 2014-12-23 | 2020-07-28 | 吉利德科学公司 | Polycyclic carbonyl pyridinone compounds and pharmaceutical use thereof |
US10206926B2 (en) | 2014-12-24 | 2019-02-19 | Gilead Sciences, Inc. | Quinazoline compounds |
US9730936B2 (en) | 2014-12-24 | 2017-08-15 | Gilead Sciences, Inc. | Quinazoline compounds |
US11304948B2 (en) | 2014-12-24 | 2022-04-19 | Gilead Sciences, Inc. | Quinazoline compounds |
EP3521282A1 (en) | 2014-12-24 | 2019-08-07 | Gilead Sciences, Inc. | Quinazoline derivatives used to treat hiv |
EP4302830A2 (en) | 2014-12-24 | 2024-01-10 | Gilead Sciences, Inc. | Quinazoline derivatives used to treat hiv |
US10548898B2 (en) | 2014-12-24 | 2020-02-04 | Gilead Sciences Inc. | Quinazoline compounds |
WO2016105534A1 (en) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Isoquinoline compounds for the treatment of hiv |
WO2016105564A1 (en) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Quinazoline derivatives used to treat hiv |
EP3960735A1 (en) | 2014-12-24 | 2022-03-02 | Gilead Sciences, Inc. | Quinazoline derivatives used to treat hiv |
WO2016105532A1 (en) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Fused pyrimidine compounds for the treatment of hiv |
US9701677B2 (en) | 2014-12-24 | 2017-07-11 | Gilead Sciences, Inc. | Fused pyrimidine compounds |
US9624195B2 (en) | 2014-12-24 | 2017-04-18 | Gilead Sciences, Inc. | Isoquinoline compounds |
US11628181B2 (en) | 2014-12-26 | 2023-04-18 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
EP3722297A1 (en) | 2015-03-04 | 2020-10-14 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
EP3321265A1 (en) | 2015-03-04 | 2018-05-16 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine compounds and their utilisation as modulators of toll-like receptors |
WO2016141092A1 (en) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
JP2018510168A (en) * | 2015-04-02 | 2018-04-12 | ギリアード サイエンシーズ, インコーポレイテッド | Polycyclic carbamoylpyridone compounds and their pharmaceutical use |
EP3736274A1 (en) | 2015-04-02 | 2020-11-11 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
JP2018188483A (en) * | 2015-04-02 | 2018-11-29 | ギリアード サイエンシーズ, インコーポレイテッド | Polycyclic carbamoylpyridone compound and pharmaceutical use thereof |
WO2016161382A1 (en) | 2015-04-02 | 2016-10-06 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
RU2712275C9 (en) * | 2015-04-28 | 2020-03-19 | Сионоги Энд Ко., Лтд. | Substituted polycyclic pyridone derivatives and prodrugs thereof |
RU2712275C2 (en) * | 2015-04-28 | 2020-01-28 | Сионоги Энд Ко., Лтд. | Substituted polycyclic pyridone derivatives and prodrugs thereof |
US9802918B2 (en) | 2015-05-29 | 2017-10-31 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
WO2017035230A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
US11066387B2 (en) | 2015-09-09 | 2021-07-20 | Incyte Corporation | Salts of a Pim kinase inhibitor |
US11505540B2 (en) | 2015-09-09 | 2022-11-22 | Incyte Corporation | Salts of a Pim kinase inhibitor |
US9862705B2 (en) | 2015-09-09 | 2018-01-09 | Incyte Corporation | Salts of a pim kinase inhibitor |
US12043614B2 (en) | 2015-09-09 | 2024-07-23 | Incyte Corporation | Salts of a Pim kinase inhibitor |
US10336728B2 (en) | 2015-09-09 | 2019-07-02 | Incyte Corporation | Salts of a Pim kinase inhibitor |
WO2017059120A1 (en) | 2015-09-30 | 2017-04-06 | Gilead Sciences, Inc. | Compounds and combinations for the treatment of hiv |
US11053215B2 (en) | 2015-10-02 | 2021-07-06 | Incyte Corporation | Heterocyclic compounds useful as Pim kinase inhibitors |
US10450296B2 (en) | 2015-10-02 | 2019-10-22 | Incyte Corporation | Heterocyclic compounds useful as Pim kinase inhibitors |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
WO2017083304A1 (en) | 2015-11-09 | 2017-05-18 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
CN108348473A (en) * | 2015-11-09 | 2018-07-31 | 吉利德科学公司 | Treat the therapeutic combination of human immunodeficiency virus |
AU2016354007B2 (en) * | 2015-11-09 | 2019-11-14 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
AU2020200995B2 (en) * | 2015-11-09 | 2022-04-07 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
KR102606625B1 (en) * | 2015-11-09 | 2023-11-27 | 길리애드 사이언시즈, 인코포레이티드 | Therapeutic Compositions for Treatment of Human Immunodeficiency Virus |
CN108348473B (en) * | 2015-11-09 | 2021-06-18 | 吉利德科学公司 | Therapeutic compositions for the treatment of human immunodeficiency virus |
EP3346995B1 (en) | 2015-11-09 | 2019-08-28 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
JP2018532811A (en) * | 2015-11-09 | 2018-11-08 | ギリアード サイエンシス インコーポレーテッド | Therapeutic composition for treating human immunodeficiency virus |
AU2016354007C9 (en) * | 2015-11-09 | 2020-10-01 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
AU2020200995B9 (en) * | 2015-11-09 | 2022-04-28 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
US11744802B2 (en) | 2015-11-09 | 2023-09-05 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
EP3632415A1 (en) | 2015-11-09 | 2020-04-08 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
US10548846B2 (en) | 2015-11-09 | 2020-02-04 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
TWI737647B (en) * | 2015-11-09 | 2021-09-01 | 美商基利科學股份有限公司 | Therapeutic compositions for treatment of human immunodeficiency virus |
KR102153996B1 (en) * | 2015-11-09 | 2020-09-09 | 길리애드 사이언시즈, 인코포레이티드 | Therapeutic composition for the treatment of human immunodeficiency virus |
KR20200106222A (en) * | 2015-11-09 | 2020-09-11 | 길리애드 사이언시즈, 인코포레이티드 | Therapeutic Compositions for Treatment of Human Immunodeficiency Virus |
AU2016354007C1 (en) * | 2015-11-09 | 2020-09-10 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
KR20180067702A (en) * | 2015-11-09 | 2018-06-20 | 길리애드 사이언시즈, 인코포레이티드 | Therapeutic composition for the treatment of human immunodeficiency virus |
CN113546052A (en) * | 2015-11-09 | 2021-10-26 | 吉利德科学公司 | Therapeutic compositions for the treatment of human immunodeficiency virus |
EP3992206A1 (en) | 2015-12-15 | 2022-05-04 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
WO2017106346A2 (en) | 2015-12-15 | 2017-06-22 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
US10654827B2 (en) | 2016-08-19 | 2020-05-19 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2018035359A1 (en) | 2016-08-19 | 2018-02-22 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
EP4265299A2 (en) | 2016-08-19 | 2023-10-25 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
US11993583B2 (en) | 2016-08-19 | 2024-05-28 | Gilead Sciences, Inc. | Therapeutic compounds |
EP3597646A1 (en) | 2016-08-19 | 2020-01-22 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2018042332A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
WO2018045144A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
WO2018064071A1 (en) | 2016-09-27 | 2018-04-05 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
WO2018064080A1 (en) | 2016-09-28 | 2018-04-05 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection |
WO2018081292A1 (en) | 2016-10-27 | 2018-05-03 | Gilead Sciences, Inc. | Crystalline forms of darunavir free base, hydrate, solvates and salts |
US10829499B2 (en) | 2016-12-02 | 2020-11-10 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors |
US10479801B2 (en) | 2016-12-02 | 2019-11-19 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors |
WO2018144390A1 (en) | 2017-01-31 | 2018-08-09 | Gilead Sciences, Inc. | Crystalline forms of tenofovir alafenamide |
EP3909949A1 (en) | 2017-02-06 | 2021-11-17 | Gilead Sciences, Inc. | Atazanavir (atv) analogues for treating hiv infections |
WO2018145021A1 (en) | 2017-02-06 | 2018-08-09 | Gilead Sciences, Inc. | Atazanavir (atv) analogues for treating hiv infections |
US10752636B2 (en) | 2017-02-06 | 2020-08-25 | Gilead Sciences, Inc. | HIV inhibitor compounds |
US11078208B1 (en) | 2017-02-06 | 2021-08-03 | Gilead Sciences, Inc. | HIV inhibitor compounds |
WO2018229798A1 (en) | 2017-06-13 | 2018-12-20 | Cipla Limited | Process for the preparation of bictegravir and intermediate thereof |
WO2018237148A1 (en) | 2017-06-21 | 2018-12-27 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
EP3960740A1 (en) | 2017-08-01 | 2022-03-02 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections |
US10851125B2 (en) | 2017-08-01 | 2020-12-01 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate |
WO2019027920A1 (en) | 2017-08-01 | 2019-02-07 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections |
EP3664896A1 (en) | 2017-08-09 | 2020-06-17 | VIIV Healthcare Company | Combinations and uses and treatments thereof |
EP3664896A4 (en) * | 2017-08-09 | 2021-06-09 | VIIV Healthcare Company | Combinations and uses and treatments thereof |
EP3664895A1 (en) | 2017-08-09 | 2020-06-17 | VIIV Healthcare Company | Combinations and uses and treatments thereof |
WO2019035973A1 (en) | 2017-08-17 | 2019-02-21 | Gilead Sciences, Inc | Choline salt forms of an hiv capsid inhibitor |
EP4046994A1 (en) | 2017-08-17 | 2022-08-24 | Gilead Sciences, Inc. | Choline salt forms of an hiv capsid inhibitor |
WO2019035904A1 (en) | 2017-08-17 | 2019-02-21 | Gilead Sciences, Inc. | Solid forms of an hiv capsid inhibitor |
US10849892B2 (en) | 2017-08-17 | 2020-12-01 | Gilead Sciences, Inc. | Choline salt forms of an HIV capsid inhibitor |
US11267799B2 (en) | 2017-08-17 | 2022-03-08 | Gilead Sciences, Inc. | Solid forms of an HIV capsid inhibitor |
US11266638B2 (en) | 2017-08-17 | 2022-03-08 | Gilead Sciences, Inc. | Choline salt forms of an HIV capsid inhibitor |
EP4092020A1 (en) | 2017-08-17 | 2022-11-23 | Gilead Sciences, Inc. | Solid forms of an hiv capsid inhibitor |
EP4382105A2 (en) | 2017-08-17 | 2024-06-12 | Gilead Sciences, Inc. | Choline salt forms of an hiv capsid inhibitor |
US11833143B2 (en) | 2017-08-17 | 2023-12-05 | Gilead Sciences, Inc. | Choline salt forms of an HIV capsid inhibitor |
US11845739B2 (en) | 2017-08-17 | 2023-12-19 | Gilead Sciences, Inc. | Solid forms of an HIV capsid inhibitor |
US11286262B2 (en) | 2017-10-06 | 2022-03-29 | Shionogi & Co., Ltd. | Stereoselective process for preparing substituted polycyclic pyridone derivatives |
EP3693373A4 (en) * | 2017-10-06 | 2021-11-03 | Shionogi & Co., Ltd. | Method for stereoselectively producing substituted polycyclic pyridone derivative |
WO2019075291A1 (en) | 2017-10-13 | 2019-04-18 | Gilead Sciences, Inc. | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors |
WO2019084020A1 (en) | 2017-10-24 | 2019-05-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
US11331331B2 (en) | 2017-12-07 | 2022-05-17 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2019113462A1 (en) | 2017-12-07 | 2019-06-13 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
US11903959B2 (en) | 2017-12-07 | 2024-02-20 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
US11278541B2 (en) | 2017-12-08 | 2022-03-22 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11253524B2 (en) | 2018-01-19 | 2022-02-22 | Gilead Sciences, Inc. | Metabolites of bictegravir |
WO2019154634A1 (en) | 2018-02-09 | 2019-08-15 | Sandoz Ag | Crystalline form of bictegravir sodium |
US11267801B2 (en) | 2018-02-15 | 2022-03-08 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2019161017A1 (en) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
US11753399B2 (en) | 2018-02-15 | 2023-09-12 | Gilead Sciences, Inc. | Therapeutic compounds |
US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
US10696657B2 (en) | 2018-02-16 | 2020-06-30 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
WO2019159199A1 (en) | 2018-02-16 | 2019-08-22 | Cipla Limited | Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof |
US11760746B2 (en) | 2018-02-16 | 2023-09-19 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
US11117886B2 (en) | 2018-02-16 | 2021-09-14 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
US11149052B2 (en) | 2018-04-06 | 2021-10-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides |
US11292812B2 (en) | 2018-04-06 | 2022-04-05 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotides |
WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
WO2019193533A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'2'-cyclic dinucleotides |
WO2019193542A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
US11453669B2 (en) | 2018-05-31 | 2022-09-27 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative |
WO2019230858A1 (en) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | Polycyclic carbamoylpyridone derivative |
US11649236B2 (en) | 2018-05-31 | 2023-05-16 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative |
EP4257137A2 (en) | 2018-05-31 | 2023-10-11 | Shionogi & Co., Ltd | Polycyclic carbamoylpyridone derivatives for the treatment of hiv |
KR20210015922A (en) | 2018-05-31 | 2021-02-10 | 시오노기 앤드 컴파니, 리미티드 | Polycyclic carbamoylpyridone derivatives |
WO2020004443A1 (en) | 2018-06-27 | 2020-01-02 | 国立大学法人北海道大学 | Arenavirus growth inhibitor comprising polycyclic carbamoyl pyridone derivative |
US11623933B2 (en) | 2018-06-28 | 2023-04-11 | Honour Lab Limited | Process for the preparation of sodium (2R,5S,13AR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13A-octahydro-2,5-Methanopyrido[1 ′,2′:4,5]pyrazino[2,1 -b] [1,3] oxazepin-8-olate and its polymorphic form |
US12037343B2 (en) | 2018-06-28 | 2024-07-16 | Honour Lab Limited | Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6,-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13A-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-B] [1,3] oxazepin-8-olate and its polymorphic form |
WO2020003151A1 (en) * | 2018-06-28 | 2020-01-02 | Honour Lab Limited | Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form |
EP4257600A2 (en) | 2018-07-03 | 2023-10-11 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
WO2020010107A1 (en) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
WO2020012408A3 (en) * | 2018-07-12 | 2020-03-05 | Laurus Labs Limited | A process for purification of protected polycyclic carbamoylpyridone derivatives |
US11634431B2 (en) | 2018-07-12 | 2023-04-25 | Laurus Labs Limited | Process for purification of protected polycyclic carbamoylpyridone derivatives |
US11944611B2 (en) | 2018-07-16 | 2024-04-02 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
WO2020018459A1 (en) | 2018-07-16 | 2020-01-23 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
WO2020028272A1 (en) | 2018-07-30 | 2020-02-06 | Gilead Sciences, Inc. | Anti-hiv compounds |
US11052087B2 (en) | 2018-07-30 | 2021-07-06 | Gilead Sciences, Inc. | Anti-HIV compounds |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
WO2020092621A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
EP4371987A1 (en) | 2018-10-31 | 2024-05-22 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
EP3653629A1 (en) | 2018-11-16 | 2020-05-20 | Sandoz AG | Acid addition salts of an integrase strand transfer inhibitor |
WO2020161744A1 (en) | 2019-02-07 | 2020-08-13 | Cipla Limited | Novel polymorphs of integrase inhibitor |
WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
US11084832B2 (en) | 2019-03-22 | 2021-08-10 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
TWI745900B (en) * | 2019-03-22 | 2021-11-11 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
EP4122537A1 (en) | 2019-03-22 | 2023-01-25 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
US11548902B1 (en) | 2019-03-22 | 2023-01-10 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
WO2020214652A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020214647A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
WO2020214663A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020214716A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | 2-imino-5-oxo-imidazolidine inhibitors of hiv protease |
WO2020236753A1 (en) | 2019-05-21 | 2020-11-26 | Gilead Sciences, Inc. | Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2020246910A1 (en) | 2019-06-03 | 2020-12-10 | Александл Васильевич ИВАЩЕНКО | ANNELATED 9-HYDROXY-1,8-DIOXO-1,3,4,8-TETRAHYDRO-2Н-PYRIDO[1,2-α]PYRAZINE-7-CARBOXAMIDES AS HIV INTEGRASE INHIBITORS |
EP3978503A4 (en) * | 2019-06-03 | 2022-12-07 | Ivachtchenko, Alena Alexandrovna | ANNELATED 9-HYDROXY-1,8-DIOXO-1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-7-CARBOXAMIDES AS HIV INTEGRASE INHIBITORS |
RU2717101C1 (en) * | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Anellated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine-7-carboxamides - integrase inhibitors, methods for preparing and using thereof |
EP3993797A4 (en) * | 2019-06-18 | 2023-10-25 | Laurus Labs Limited | Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof |
WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
US11358711B2 (en) | 2019-06-20 | 2022-06-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
WO2021011544A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
US11807625B2 (en) | 2019-11-26 | 2023-11-07 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
WO2021107066A1 (en) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
US11697652B2 (en) | 2020-02-24 | 2023-07-11 | Gilead Sciences, Inc. | Tetracyclic compounds and uses thereof |
WO2021173522A1 (en) | 2020-02-24 | 2021-09-02 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
CN113698420A (en) * | 2020-05-22 | 2021-11-26 | 上海迪赛诺生物医药有限公司 | Novel crystal form of bicalutavir sodium and preparation method thereof |
US11680064B2 (en) | 2020-06-25 | 2023-06-20 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
WO2021262990A1 (en) | 2020-06-25 | 2021-12-30 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
WO2022072520A1 (en) | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
WO2022087149A2 (en) | 2020-10-22 | 2022-04-28 | Gilead Sciences, Inc. | Interleukin-2-fc fusion proteins and methods of use |
CN114426540A (en) * | 2020-10-29 | 2022-05-03 | 上海拓界生物医药科技有限公司 | Pyrido [1,2-a ] pyrazine-1, 8-diketone prodrug derivatives, preparation method and application thereof |
CN114426540B (en) * | 2020-10-29 | 2024-04-26 | 上海拓界生物医药科技有限公司 | Pyrido [1,2-a ] pyrazine-1, 8-dione prodrug derivatives, preparation method and application thereof |
WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
WO2022159387A1 (en) | 2021-01-19 | 2022-07-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
US11897892B2 (en) | 2021-01-19 | 2024-02-13 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
EP4321217A2 (en) | 2021-01-19 | 2024-02-14 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
EP4281076A4 (en) * | 2021-01-22 | 2024-07-31 | Laurus Labs Ltd | Processes for purification of bictegravir intermediates |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023102529A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
WO2023102239A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
US11787825B2 (en) | 2021-12-03 | 2023-10-17 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
WO2023196875A1 (en) | 2022-04-06 | 2023-10-12 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
EP4310087A1 (en) | 2022-04-06 | 2024-01-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
US12024528B2 (en) | 2022-04-06 | 2024-07-02 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
US12054496B2 (en) | 2022-04-06 | 2024-08-06 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7301918B2 (en) | Polycyclic carbamoylpyridone compound and pharmaceutical use thereof | |
OA17631A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13815937 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013815937 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2893843 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 239316 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2015549669 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001036-2015 Country of ref document: PE Ref document number: MX/A/2015/008009 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12015501445 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201591027 Country of ref document: EA Ref document number: IDP00201503852 Country of ref document: ID |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015014714 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20200093 Country of ref document: MD Kind code of ref document: A Ref document number: 20150064 Country of ref document: MD Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A 2015 0064 Country of ref document: MD |
|
ENP | Entry into the national phase |
Ref document number: 20157019194 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15165942 Country of ref document: CO Ref document number: 15265717 Country of ref document: CO Ref document number: CR2015-000380 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 2013361401 Country of ref document: AU Date of ref document: 20131219 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015014714 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150619 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12016500389 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 245780 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000694-2016 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2016/0407 Country of ref document: RS |
|
WWE | Wipo information: entry into national phase |
Ref document number: 247311 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017279 Country of ref document: CR Ref document number: CR2017-000279 Country of ref document: CR |